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The advent of modern high throughput sequencing (HTS) technology has resulted in the 
resurgence of phage display as a powerful technique in screening peptide and protein 
libraries for mutations and/or protein fragments with desired properties. As the protein or 
peptide is covalently tethered to (or “displayed” on) the surface of the bacteriophage, its 
corresponding genetic material may be rapidly identified and analyzed using DNA 
sequencing technologies. As the earliest applications of phage display were limited by the 
available methods (low-throughput Sanger DNA sequencing), repetitive rounds of 
selection and amplification were required, and only a small portion of the selected phage 
could be analyzed. Coupling phage display with HTS creates a new high throughput 
platform, termed high throughput phage display, with which to quickly and without bias 
screen vast libraries of peptides and proteins for novel binding interactions, stability, and 
kinetics. High throughput phage display allows characterization of the population of a 
library of >106 phage prior to and after selection to determine the level of enrichment or 
depletion of individual clones within the library. In this dissertation, I will highlight the 
potential of high throughput phage display with two different yet complimentary 
applications: 
 
Streptococcus pyogenes (GAS) is a pathogenic bacteria that activates the fibrinolytic 
system via a secreted virulence factor, streptokinase, facilitating GAS dissemination 
throughout the human host and evasion of the host immune system. A small, bioactive 
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compound that inhibits streptokinase expression was previously developed and validated 
in a humanized mouse model of GAS septicemia. The mechanism of action and target of 
the compound within GAS remain unknown. A candidate gene was ruled out using 
genetic studies so an unbiased biochemical approach to identify GAS proteins involved in 
its mechanism of action was undertaken. Randomly fragmented GAS genomic DNA was 
cloned into a phage display vector in order to create a library of phage displaying GAS 
peptides on their surface. Although the utility of this library was hindered by technical 
difficulties during preparation, it demonstrated feasibility of constructing large and 
diverse phage display libraries that could be useful in other applications. 
 
As a serine protease inhibitor (serpin), plasminogen activator inhibitor-1 (PAI-1) 
regulates the fibrinolytic system by inhibiting the plasminogen activators, tissue-type and 
urokinase-type plasminogen activator PAI-1 undergoes spontaneous conformational 
conversion to an inactive, latent state with a half-life of 2 hours. Two previous whole 
gene mutagenesis studies identified mutations that stabilize the active conformation of 
PAI-1 but ultimately only characterized the effects of 1.2% of all possible amino acid 
substitutions on PAI-1 stability. Here we report the construction and screening of a phage 
display library of PAI-1 variants to examine the mutational landscape with respect to 
functional stability. Using high throughput phage display, we surveyed 74% of all 
possible amino acid substitutions within PAI-1 resulting in identification of 1509 
substitutions that decrease the functional half-life of PAI-1 and 492 mutations that 
stabilize the active conformation, including the majority of previously reported 
mutations. Our approach provides a massively parallel platform to comprehensively 
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analyze the largely unknown mutational landscape of PAI-1 and the effect of single 
amino acid substitutions on functional stability of PAI-1. This approach could be applied 
in the future to characterize the clinical significant of all possible human mutations and to 
generate PAI-1 variants with altered target specificity and the potential to treat human 










F-specific filamentous bacteriophage (“phage”) are DNA viruses that infect bacterial 
hosts via interaction with the F-pilus on the surface of some bacteria.1-4 F-specific 
filamentous phage include fd, f1, and M13.5 Phage particles (virions) resemble long 
cylindrical filaments where one end is capped by coat proteins pVII and pIX, the central 
portion is covered with pVIII (the major coat protein) and the opposite end is capped by 
pIII and pVI (Figure 1-1).3, 6, 7 Contained within the viron body is the single-stranded 
phage DNA genome. Phage infection is dependent upon the N-terminal domain of the 
pIII coat protein, which first binds to the F-pilus on the bacterial outer membrane, 
inducing a conformational change in pIII. This change allows binding of a C-terminal 
domain of pIII to the TolA receptor in the periplasm.1, 6, 8-10 Following binding of pIII to 
the TolA receptor, the phage is inserted into the inner membrane of the bacteria and its 
DNA genome is trafficked to the cytoplasm by an unknown mechanism.6  
 
Within the cytoplasm, the single-stranded phage genome replicates episomally by a 
rolling circle mechanism to generate a double stranded genome that serves as a template 
for transcription and translation of viral proteins.2, 6 After translation, viral coat proteins 
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span the inner membrane of the bacteria in preparation for virion assembly.11 Once 
sufficient viral proteins have been produced, pV binds to the single stranded DNA viral 
genome once the double stranded replicative form has been unwound for replication, 
preventing further replication and sequestering for assembly into viral particles.12 
 
The single stranded viral DNA contains a packaging signal that forms a hairpin and 
interacts with coat proteins pVII and pIX, which comprise one end of the virion.6, 13, 14 
This binding initiates virion assembly, which occurs as the phage genome is secreted into 
the periplasm and then the extracellular space. The single stranded DNA genome acts as 
a scaffold upon which the major coat protein pVIII, located along the inner membrane, is 
assembled as the DNA is translocated across the membrane.15 Assembly is complete once 
pIII and pVI bind the terminal end of the virion and it is released from the cell. Because 
filamentous phage do not require host cell lysis for release of newly synthesized phage, 
very high amounts of virus can be continually released into cell culture media (on the 
order of 1013 phage / mL).16 
	
The wild-type phage genome contains approximately 6400 nucleotides, but the virion 
size is capable of expanding proportionally to the genome contained within, allowing 
foreign DNA of up to twice that size to be cloned into the phage genome, making phage a 
valuable tool for cloning and other biochemical applications, especially with large 






In 1985, George Smith described cloning a fragment of foreign DNA between two 
domains of the M13 pIII gene.19 When these fragments were cloned in such a way that 
the open reading frame was kept intact, the function of pIII was not disrupted, and the 
peptide coded by the foreign DNA was displayed on the surface of the phage such that it 
could be recognized by specific antibodies.19, 20 This discovery gave rise to the field of 
phage display as large libraries of these “fusion phage” could be constructed such that 
each phage displayed a different peptide, peptide fragment, or mutant protein on its 
surface.20-22 Scott and Smith went on to develop an epitope library where each phage 
displayed a unique random hexamer peptide on it’s surface23 (discussed further in 
“Applications of Phage Display”). This study demonstrated the possibility of constructing 
large (2×108 unique clones) phage display libraries that could be screened to identify 
clones that interact with a specific target.23 Because these fusion phage retained the 
ability to infect bacteria, a large pool of phage could be generated, screened against a 
target to select clones that bind, and then bound phage could transduce bacteria. These 
phage-transduced bacteria now carried the phage DNA sequence, which could be isolated 
and sequenced in order to determined DNA inserted into pIII and thus the peptide 
displayed on the surface that bound to the target; or the DNA could be used to generate 
additional phage to repeat the screen with an already purified pool of phage in order to 
isolate phage displaying the highest affinity to the target molecule.18, 20, 23, 24  
 
The phage vector used by Scott and Smith, fUSE5, contained a tetracycline resistance 
gene and only a single copy of the pIII gene.23 This allowed for quantifying phage by 
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infecting bacterial cells sensitive to tetracycline and counting the number of transduced 
units (cells conferred resistance by transduction with phage carrying tetracycline 
resistance).23 As only a single copy of the pIII gene was present, upon cloning of the 
foreign DNA into the pIII gene, all copies displayed on the surface of the phage (5 in 
total) would contain the foreign peptide fusion (Figure 2A).23 Any foreign DNA insert 
that altered the reading frame of pIII, or introduced a stop codon, would result in lack of 
production of pIII and thus non-infectious phage that could not be propagated.23 An 
alternative vector for phage display, termed a phagemid, was developed by Carlos Barbas 
and Richard Lerner, shortly thereafter.25, 26 Phagemids contain an antibiotic resistance 
cassette and are capable of replicating within bacteria because they contain both a phage 
and bacterial origin of replication, allowing phage-independent propagation.27. Inclusion 
of a phage packaging signal allows phagemids to be packaged within phage particles like 
a typical phage genome.18, 25, 27 Unlike the fUSE vector or a typical phage genome, a 
phagemid only carries the pIII gene and not the rest of the major coat proteins required 
for phage assembly and secretion.25-27 “Super-infection” of bacteria harboring the 
phagemid by a filamentous phage whose genome codes for the additional coat proteins (a 
“helper phage”) is thus required for assembly and secretion of fusion phage particles.25-27 
In the phagemid constructed by Barbas and Lerner, the foreign peptide was cloned as a 
fusion to the C-terminal domain of pIII, replacing the N-terminal domain required for 
infection.25, 26, 28. The WT pIII provided by the helper phage had an intact, full-length 
pIII, enabling virions produced as a result of super-infection to transduce naïve bacteria 
and propagate the phagemid vector.18, 25-27 Likewise, the super-infected cells producing 
phage particles will contain a mixture of WT and foreign-peptide fused pIII coat proteins 
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that will be incorporated into the secreted phage (Figure 1-2B).18, 27 In contrast to the 
fUSE5 vector, a phagemid containing a foreign DNA-pIII fusion where insertion of 
foreign DNA that contains stop codons or alters the reading frame of pIII can still be 
propagated by phage particles because the WT pIII provided by the helper phage can bind 
the F-pilus of bacteria and initiate canonical filamentous phage transduction.6, 18, 23, 27, 28 
In such an instance, however, no fusion peptide would be displayed on the surface of the 
phage. Felici and colleagues demonstrated that foreign peptides could also be displayed 
as fusions to the major coat protein, pVIII, as well.18, 29 Similar to the fUSE system, this 
fusion resulted in a multivalent display, with many copies of the foreign peptide 
displayed on the surface of the phage (Figure 1-2C).29 A considerable limitation using 
pVIII to display a foreign peptide was the restriction in size; only very small peptides 
were capable of being displayed as a fusion to pVIII.3, 6, 7, 18  
	
APPLICATIONS OF PHAGE DISPLAY 
	
Phage display offered a novel approach to screening large libraries of peptides to assay 
binding, function, stability, and much more.18, 27. A significant advantage that phage 
display offered over other techniques for surveying proteins was that the displayed 
peptide was physically linked to the coding DNA, all within a particle capable of 
replicating within bacteria.19 Using phage display, vast libraries of peptides can be 
screened against a target and then the DNA contained within the phage (or phagemid) of 




Parmley and Smith demonstrated that it was possible to utilize this replicative ability of 
phage in order to purify clones present at very low frequency within a starting library by 
introducing an amplification step during the affinity purification process.20 Using this 
approach, a library was screening against a target and after non-specifically bound phage 
were washed away and remaining phage were eluted, the elution fraction was used to 
infect fresh host bacteria in order to amplify the eluted phage and construct a “post-
selection” library with which the screen could be repeated (Figure 1-3A).20 Presumably, 
after a single round of amplification, the background phage that did not bind the target 
specifically were decreased while the frequency of the desired phage was increased and 
amplification of this pool would result in a greater number of the desired phage to be 
screened in the second process. Parmley and Smith observed that such an approach 
resulted in enrichment of 104 after a single round of selection, 105 after two rounds of 
selection and re-amplification, and 107 after three rounds.20 Using this iterative selection 
and re-amplification procedure, phage display became a powerful technique with which 
to study proteins.18, 24, 27 
 
By inserting a string of 18 random nucleotides [(NNK)6, where N = A, C, G, or T and K= 
G or T, sufficient to generate codons for all twenty amino acids and only one stop codon] 
between the N and C domains of pIII, Smith and Scott constructed a very large (2×108 
unique clones) library of phage displaying unique, random hexapeptide on their surface.23 
These “epitope libraries” as they were called were quickly adopted and used to map the 
epitopes of proteins recognized by antibodies, including a monoclonal antibody raised 
against human plasminogen activator inhibitor-1 (PAI-1)30 (an extensive list can be found 
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in Ref. 18). Epitope libraries also displayed diagnostic potential as they were screened 
against sera from patients suffering from rheumatoid arthritis to identify antigenic 
epitopes targeted in autoimmune disease.31, 32 This epitope mapping strategy later evolved 
to include cysteine residues flanking the random region to form a disulfide bond and 
conformationally constrain the displayed random peptide.33 Random peptide libraries 
were also utilized to identify novel peptides that bind to streptavidin22 and biotin34. The 
therapeutic potential of phage display was demonstrated in 1996, when a random peptide 
library was screened against the erythropoietin receptor.35 By sequencing phage screened 
against the receptor and identifying the displayed peptide, Wrighton and colleagues were 
able to decipher a specific motif that was involved in receptor binding. Using this as a 
guide, they were able to rationally design novel agonists of the erythropoietin receptor.35 
Random peptide libraries have also been used for in vivo screens, such as when 
Pasqualini and Ruoslahti injected phage displaying a random sequence of seven amino 
acids into mice and demonstrated specific homing of certain peptides to different vascular 
beds.36 They identified a novel cerebrovascular targeting peptide that when tagged to red 
blood cells, led to an accumulation of those blood cells within the brains of mice.36 
Finally, as identification of the displayed peptide is confirmed by the foreign DNA 
cloned into the phage DNA or phagemid and not the protein displayed on the phage 
directly, phage display has been used to characterize the substrate specificity of proteases 
using an approach termed “substrate display” where phage are immobilized with a 
random peptide between the immobilization target and the phage body, containing the 
DNA, and then subjected to cleavage by a protease of interest. Phage which express a 
peptide recognized and cleaved by the protease will be released from the immobilization 
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agent and can be sequenced in order to determine the substrate specificity of the screened 
protease. Such screens have characterized the substrate specificity of enzymes involved 
in coagulation, including Factor Xa37, tissue plasminogen activator (tPA)38, urokinase-
type plasminogen activator (uPA)39, thrombin40, and ADAMTS1341 (Reviewed in 42). 
 
Phage display also offers a powerful tool for studying structure-function relationship 
within specific proteins. Libraries can be constructed from a fragmented gene, a 
randomly mutated gene, or even from a whole genome. Using a mutant phage library 
generated from a thrombin receptor ligand, Doorbar et al isolated a novel peptide that 
acted as a thrombin receptor antagonist and inhibited platelet aggregation.43 Similar work 
has been done using random fragments of von Willebrand Factor to confirm that its 
platelet binding ability is exclusive to the A1 domain and that the cystine loop is required 
for optimal binding.44 Jacobsson and colleagues constructed a library from randomly 
fragmented DNA from Staphylococcus aureus, demonstrating that bacterial chromosomal 
genetic material could be used to generate a phage display library.45, 46 This library 
resulted in the identification of novel IgG and fibronectin binding proteins not previously 
characterized in S. aureus.45  
 
It is worth noting that all phage studies reported before 2010 (and all but one of the 
studies discussed up to this point) were performed using the original procedure described 
by Parmley and Smith20 and Scott and Smith23, in which repetitive rounds of selection 
and re-amplification are required to enrich for clones present in the starting library at very 
small levels. 20 This procedure involved screening the library against a target of interest, 
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washing away unbound or loosely associating phage, eluting specifically bound phage, 
using eluted phage to infect bacteria and re-amplify the library, and repeating the 
screening and re-amplification process for several cycles.19, 23, 27. After the final selection, 
the eluted phage is used to transduce bacteria, allowing infected cells to grow in the 
presence of the selection antibiotic. Single colonies of bacteria are harvested, and the 
phage vector or phagemid is sequenced by Sanger sequencing to determine the identity of 
the displayed peptide (Figure 1-3A).27 Sanger sequencing allows for accurate sequencing 
of long (~900 basepairs for a single read) DNA fragments but is low throughput.47 
Because many phage libraries are very diverse, Sanger sequencing is an impractical 
approach for assessing the complexity of an entire phage display libraries of up to 106 
unique clones; in 2009, Dias-Neto and colleagues estimated that to assay 1×106 phage 
clones by Sanger sequencing, it would take well over 1000 days and $1 million.48 This 
limits the power of these studies significantly, because without knowing the complexity 
of the starting library, it is impossible to determine to what degree a specific clone has 
been enriched (or depleted). 
 
Another important limitation of conventional phage display is the requirement for 
repetitive rounds of selection and re-amplification required to enrich for, and thus detect 
by sequencing, clones that are present at very low levels in the starting library. In the 
early days of phage display, Jamie Scott and George Smith postulated that specific high-
affinity interactions between targets and phage in the library might not be detected if 
those phage are lost during the library amplification steps between selections and that 
differences in growth rates of clones might introduce bias into the selected library.23 The 
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latter was later demonstrated to be a legitimate concern by Brammer et al who described 
a mutation present in the Shine Delgarno sequence of a particular clone within a 
commercially available phage display library. This mutation resulted in faster 
amplification and false identification of the displayed peptide, HAIYPRH, as a novel zinc 
binding protein.49 The same peptide had previously been identified as a novel peptide that 
binds to human umbilical vein endothelial cells50, human bronchial epithelial cells51, and 
polystyrene plates52. 
 
HIGH THROUGHPUT SEQUENCING AND HIGH THROUGHPUT PHAGE 
DISPLAY 
	
High throughput sequencing (HTS; also called Next Generation or “Next Gen” 
sequencing) was developed in the early and mid-2000s. There are several different 
platforms that can be used to perform HTS, but this discussion will focus mainly on the 
Illumina sequencing platform (https://www.illumina.com/). In contrast to Sanger 
Sequencing, HTS relies on reversible chain termination in combination with fluorescent 
nucleotides.47, 53 DNA molecules are annealed to a chip and fluorescent chain terminating 
bases are added.53 The parent strand of DNA to be sequenced is extended one nucleotide 
at a time, with a camera capturing the fluorescent signal of the nucleotide incorporated at 
each position. After each nucleotide is incorporated, the chain termination is reversed and 
the next fluorescent nucleotide is incorporated. 53 Because DNA is amplified and 
sequenced in clusters, many thousands of sequences can be simultaneously read on a 
single chip.47, 53-55 In 2008 it was estimated that several hundred machines performing 
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Sanger DNA sequencing would be required to match the amount of data generated by a 
single HTS machine in one day.54 As a result of such high throughput sequencing, when 
using HTS to analyze phage libraries, iterative rounds of screening and re-amplification 
are not required and the entire eluted pool of phage can be analyzed after a single 
selection event (Figure 1-3B). 
	
In 2010, phage display was adopted for use with HTS, termed high throughput phage 
display. Fowler et al screened a library of over 600,000 variants of a human WW domain 
β-sheet displayed on phage and characterized the mutational landscape with respect to 
binding a natural ligand. Their high throughput mutational scan validated the results of 
previous targeted studies on the WW domain and laid the groundwork for future high 
throughput phage display experiments. 56 Since then, synthetic human peptidome libraries 
have been displayed on phage and used to identify the targets of autoantibodies found in 
the serum of patients with various autoimmune diseases.57, 58 By displaying the antibody 
variable region on phage, antibody discovery and maturation was expedited. 59 Phage 
libraries have even made headlines in the lay press, such as when a library constructed 
from the genomes of all viruses known to specifically infect humans was generated 
(https://www.nytimes.com/2015/06/05/health/single-blood-test-for-all-virus-
exposures.html). Screening this library against human patient serum offers the potential 





High throughput phage display also offers the potential to assess the complexity of the 
library before and after selection, making it possible to measure the precise enrichment of 
specific clones within the library. Not only can enrichment be measured in order to 
identify candidate peptides that bind the target, but depletion can also be measured to 
determine the sequences of peptides that do not interact with the target. Kretz and 
colleagues took advantage of this strategy in using HTS to refine earlier phage display 
approaches designed to characterize the substrate specificity and preferences of 
thrombin.61 Whereas a previous study by Vindigni40 probed the effect of eight targeted 
mutations on substrate specificity for thrombin, Kretz examined over 6,700 unique 
sequences and was able to characterize not only which residues were preferred, but which 
residues interfered with cleavage and were selected against by thrombin substrate phage 
display.61 
 
The ability of HTS to examine the complexity of the phage library at every point in the 
screening process has also opened the door for large scale kinetic assays. Kretz et al 
constructed a library of randomly mutagenized fragment of von Willebrand factor (VWF) 
to examine the substrate recognition landscape of ADAMTS13. By determining the 
number of specific VWF displaying phage clones left uncleaved at multiple specific time 
points, they could estimate the apparent kinetics of ADAMTS13 for specific VWF 
mutants, something not previously done using phage display.41 This “massively parallel 
enzyme kinetics” as it was dubbed, offers a new application of high throughput phage 




THE SERPIN FAMILY OF PROTEINS 
As the name suggests, Serine protease inhibitors (serpins) are inhibitors of serine 
proteases, acting as suicide inhibitors, where a single serpin molecule can only inhibit 
one protease molecule.62 Serpins are found in all domains of life: animals, plants, 
prokaryotes, and viruses.63 In humans the serpin superfamily of proteins consists of 36 
members, most of which possess an inhibitory function.63 Some serpins are capable of 
inhibiting other families of proteases, including cysteine proteases.64 Non-inhibitory 
serpins serve other functions, such as transporting hormones in the blood 65, 66, assisting 
in protein folding following a stress response as chaperone proteins67, 68, and non-
protease-related inhibition of tumor growth69 (Reviewed in 62 and 63). 
 
All inhibitory serpins share a common mechanism of action wherein a flexible reactive 
center loop (RCL) extends above the central structure of the molecule and acts as “bait” 
for the target protease by mimicking the natural substrate (Figures 1-4A,B).70 The serpin 
and protease form a stable acyl intermediate and the active-site serine of the protease 
hydrolyses the P1-P1’ bond within the RCL (Figure 1-4B). Following this cleavage 
event, the P1 residue forms a covalent bond with the active site serine, tethering the 
protease to the serpin.71, 72 This is followed by the energetically favorable insertion of the 
N-terminal residues of the RCL into the central portion of the molecule as β-strand 4 in 
β-sheet A (s4A), carrying the tethered protease to the opposite side of the molecule in a 
pole-to-pole transition.73 This structural transformation renders both the serpin and the 
serine protease inactive and the entire serpin-protease complex is targeted for 
degradation.74-76 Serpins can also undergo cleavage of the P1-P1’ carbonyl bond without 
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subsequent inhibition of the protease, an event termed substrate behavior (Figure 1-
4C).63, 77 
	
Serpin dysfunction has been implicated in a number of human diseases (Reviewed in 70 
and 63). The first described and most well characterized is emphysema secondary to α1-
antitrypsin (A1AT, SERPINA1) deficiency.78, 79 It is estimated that 10% of individuals of 
European descent are heterozygous for one of the two most common mutations that result 
in A1AT deficiency.78, 80 Polymerization of serpins, specifically neuroserpin (SERPINI1), 
has been implicated in neurological diseases secondary to inclusion body formation.81, 82 
Alteration of serpin specificity can lead to disease, as seen in α1-antitrypsin Pittsburgh, 
which contains a point mutation at the P1 site of the RCL.83 This single substitution from 
a methionine to an arginine results in altered specificity of the serpin from inhibiting 
neutrophil elastase to inhibiting the pro-coagulant enzyme thrombin leading to fatal 
bleeding in one patient.83  
	
PLASMINOGEN ACTIVATOR INHIBITOR-1 
Plasminogen activator inhibitor-1 (PAI-1, SERPINE1) is a serpin that contributes to the 
regulation of thrombosis and hemostasis as the primary inhibitory of tissue-type and 
urokinase-type plasminogen activators (tPA and uPA, respectively).84, 85 tPA and uPA are 
serine proteases that activate the zymogen plasminogen to plasmin.86 Activated plasmin 
dissolves blood clots by degrading fibrin, an insoluble protein that forms the structural 
backbone of most blood clots.87	Plasma PAI-1 down regulates the fibrinolytic response 
by inhibiting plasminogen activation, with loss of PAI-1 resulting in unrestricted 
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degradation of fibrin clots and a bleeding diathesis.88-90 Individuals homozygous for a 
null mutation in SERPINE1 display bleeding phenotypes that can range from mild to life 
threatening, while heterozygous individuals are asymptomatic.91, 92 
 
PAI-1 has been implicated in a number of other diseases, including cardiovascular 
disease with increased levels being associated with increased risk of atherosclerosis and 
subsequent myocardial infarction93-95 Elevated levels of PAI-1 have also been associated 
with development of diabetes mellitus type 2 as well as the metabolic syndrome.96, 97 In 
malignant disease, PAI-1 has been implicated as a factor that aids in tumor growth and 
development98, 99 Decreased levels of PAI-1 on the other hand, have been associated with 
improved wound healing in mice100. In 2017, it was reported that Amish individuals 
heterozygous for a null mutations in SERPINE1 showed diminished signs of cellular 
aging and had longer life spans compared with individuals from the same community 
who were wildtype for SERPINE1.101 
 
Among serpins, PAI-1 exhibits two unique properties. First, the mature, active form lacks 
any cysteine residues facilitating large scale recombinant production in bacterial 
expression systems.102, 103 Second, PAI-1 undergoes a spontaneous transition from an 
active conformation to a more thermodynamically stable, but inactive, latent 
conformation (Figure 1-4D).104 At physiologic temperature and pH, this latency transition 
occurs rapidly, with a half-life of approximately two hours.105, 106 During the latency 
transition, the N-terminal portion of the RCL spontaneously inserts into the central β-
sheet A as a new β-strand, (strand 4, s4A) via a mechanism that mirrors that which occurs 
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during serine protease inhibition. However, insertion of the RCL as s4A renders the P1-
P1’ residues inaccessible and the latent PAI-1 incapable of inhibiting its target protease 
(Figure 1-4D).107 The latent molecule can only be reactivated by denaturation followed 
by refolding.108 Interestingly, this PAI-1 latency conversion is conserved in many 
vertebrates, including cartilaginous fish, despite less than 50% sequence identity with 
humans, suggesting an important function of this conformational switch.109 
 
PAI-1 was first displayed on filamentous phage in 1993110 and until recently was the only 
serpin to have been displayed successfully on the surface of a bacteriophage (Scott et al 
reported display of A1AT on T7 lytic phage in 2014111). In 2001, Stroop et al screened a 
library of approximately 10 million PAI-1 variants that had been randomly mutagenized 
in order to screen for mutations that increased functional stability.112, 113 This resulted in 
the identification of several clones that increased the functional half-life of PAI-1 more 
than 50-fold.112 Combining these data with those of an earlier study that used randomly 
mutated PAI-1 expressed in λ phage to identify mutations with a prolonged half-life for 
the latency transition114, only 84 of the over 7,500 possible amino acid substitutions have 
been characterized with respect to the functional half-life of PAI-1. Refining these 
screens with the power of high throughput phage display has the potential to offer insight 






Figure 1-1: Structure of filamentous phage 
Filamentous bacteriophage, such as M13, are composed of five coat proteins that surround the single 
stranded phage genome. pVIII, the major constituent of the coat protein forms a cylinder which is capped at 
either end by a pVI/pIII or pVII/pIX complex. pIII binds to the F-pilus of bacteria to initiate infection. 
  










Figure 1-2: Options for display of fusion peptides on surface of filamentous phage 
Fusion peptides can be displayed on different coat proteins of the filamentous phage. (A) depicts foreign 
peptide displayed using a fUSE5 vector approach, where the foreign DNA is cloned between the N-
terminal and C-terminal domains of pIII. This results in display of the fusion peptide on all copies of pIII 
on the phage surface. As the N-terminal domain of pIII is intact, these phage retain their infective ability. In 
(B), an alternate form of pIII display is depicted, where the N-terminal domain of pIII has been replaced by 
the foreign DNA coding for the peptide to be displayed. This fusion gene is carried on a phagemid that 
does not contain all genes necessary for production of the other major coat proteins, requiring the addition 
of a WT helper phage for production of phage particles. As the helper phage provides the WT pIII gene, 
phage will display a heterogeneous mix of WT and fusion-pIII on their surface with only WT pIII 
maintaining their infective ability. Foreign peptides can also be displayed on different coat proteins, such as 
pVIII, as depicted in (C). Display on pVIII is limited to small peptides. A pVIII phagemid:helpher phage 
system can be used to produce phage with a heterogeneous mix of WT and fusion-pVIII proteins on their 
surface (not shown). In (A) and (C) the foreign DNA is cloned directly into the phage genome vector, 



















Figure 1-3: Methods of screening for enrichment from phage libraries 
(A) The process of screening a phage display library as pioneered by George Smith and colleagues, 
involving several repetitive rounds of selection and library re-amplification to enrich for specific binding 
interactions within the library. (B) A high throughput phage display approach where a single round of 





























































Figure 1-4: Plasminogen activator inhibitor-1 (PAI-1, SERPINE1) structural 
conformations 
Structures of the (A) active form of PAI-1, demonstrating the flexible RCL (orange) extended above central 
portion of serpin body, including β-sheet A (blue) (PDB: 1DVM) (Orange dotted line indicates residues not 
resolved in original crystal structure). (B) Michaelis complex of PAI-1 with uPA (gray). P1-P1’ residues 
are depicted as red spheres. P1-P1’ scissile bond is cleaved by the protease active site serine (PDB: 3PB1). 
(C) Cleaved PAI-1 that is no longer capable of inhibition of uPA (PDB: 3CVM). (D) Latent PAI-1 in 
which RCL has inserted into β-sheet A as strand 4 (s4A). Latent PAI-1 is incapable of inhibition of uPA or 








CODY IS NOT REQUIRED FOR CCG-2979-MEDIATED INHIBITION OF 





Infectious disease is the second leading cause of death worldwide.115 Unfortunately, 
several challenges face modern medicine in the fight against infectious disease, including 
emerging resistance to existing drugs and the lack of new antibiotic compounds. The field 
of antibiotic discovery grew rapidly following the identification and characterization of 
penicillin but has slowed considerably, with only seven new antibiotics gaining FDA 
approval from 2000 to 2010.116 Occurring in tandem with this drop-off in discovery of 
drugs targeting pathogenic bacteria is the rise of antibiotic resistance, especially in 
hospital settings. Contributing to the evolution of antibiotic resistance is the selective 
pressure placed on the bacteria by the antibiotics themselves and the limited scope of 
bacterial pathways targeted by available antibiotics.117, 118 Conventional antibiotics target 
bacterial processes essential for viability and replication, thus promoting the selection of 
bacterial cells harboring mutations that limit the effectiveness of the drug without 
attenuating growth and replication.119 A novel approach to antibiotic therapy involves 
targeting the genes and proteins responsible for bacterial virulence factors within a given 
host. By targeting and inhibiting virulence rather than growth and viability, the bioactive 
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compound would theoretically exert less selective pressure while at the same time 
rendering the bacteria non-infectious.120 
 
Streptococcus pyogenes, also known as group A streptococcus (GAS), is a gram-positive 
bacterium responsible for a wide range of infections and a major cause of infectious 
disease-related morbidity and mortality. The World Health Organization estimates GAS 
is responsible for over two million new cases of severe infections and invasive disease 
every year leading to at least 780,000 deaths worldwide.121 Among the virulence factors 
produced by GAS that aid in its colonization, invasion, and dissemination is streptokinase 
(SK).122, 123 SK activates the fibrinolytic system by allosterically binding to the 
circulating zymogen plasminogen and inducing a conformational change, thereby 
enabling the streptokinase-plasminogen complex to activate plasminogen to active 
plasmin, which can in turn degrade fibrin or generate additional units of plasmin from 
plasminogen, leading to an amplification of fibrinolysis and ultimate degradation of a 
thrombus. 124-129 Previous work has demonstrated that SK from human pathogenic GAS 
exhibits species specificity toward human plasminogen and the interaction between SK 
and human-plasminogen is crucial for virulence and infectivity in a humanized-mouse 
model of invasive streptococcal disease.130  
 
As a known virulence factor in invasive streptococcal disease, SK was proposed as a 
potential candidate target for anti-virulence drug development.123, 130, 131 With this in 
mind, previous work from our laboratory identified bioactive compounds that inhibit 
streptokinase gene (ska) expression without attenuating bacterial growth. A lead 
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compound (CCG-2979) was identified from a library of 55,000 small molecules and was 
shown to inhibit streptokinase activity and reduce mortality in a humanized mouse model 
of GAS septicemia.132 Transcriptome profiling of GAS treated with a commercially 
available analog of CCG-2979 showed significantly altered expression profiles for ~29% 
of GAS transcripts, including a nearly 4-fold reduction in ska mRNA levels. 132 However, 
the direct target of this small molecule remained unknown. 
 
CodY was originally identified as a transcriptional repressor in Bacillus subtilis, but is 
now thought to function as a global transcriptional regulatory protein found in many low-
GC content gram-positive pathogenic organisms, including multiple Bacillus and 
Clostridium species, Listeria monocytogenes, Staphylococus aureus, and GAS.133, 134 
Within GAS, CodY has been shown to regulate numerous genes (17% of the genome), 
including ska.135 The major function of CodY in bacteria is to serve as a sensor of 
available nutrients, specifically guanosine triphosphate (GTP) and branched chain amino 
acids (isoleucine, leucine, and valine).136 When concentrations of these nutrients are 
sufficiently high, CodY binds to DNA to modulate the expression of various genes.137, 138 
Inactivation of GAS codY resulted in 2.5-fold reduction in ska expression and an overall 
gene expression profile similar to that of GAS treated with CCG-2979 (Supplementary 
Figure 2-1).139 Based on these observations, we hypothesized that CodY could be the 
target of CCG-2979, leading to inhibition of SK expression.  
 
 





Studies were performed using virulent GAS strains UMAA2616 (serotype M1) and 
MEW123 (serotype M28). 140-142 All GAS strains were cultured in Todd Hewitt-broth 
(Becton, Dickinson and Company, Sparks, MD) supplemented with 0.2% yeast extract 
(US Biological, Swampscott, MA) (THY) and 100 µg/mL streptomycin.  
 
A CodY knockout strain was generated by insertional mutagenesis using pSPC18 (a 
generous gift from Michael Watson Jr., University of Michigan), which harbors a 
spectinomycin resistance cassette (aad9).143 Using NEBuilder High Fidelity DNA 
Assembly (New England BioLabs, Ipswich, MA) a 617 bp fragment of codY (+83 to 
+699) was cloned into the BamHI and HindIII sites of the pSPC18 plasmid 
(pSPC18::codY) using primers (5’-
TAAAACGACGGCCAGTGCCAATAACACAATGGCATCTCG-3’ and 5’-
ATTCGAGCTCGGTACCCGGGAATCCCTGCACTTTCTAG-3’) (Figure 2-1) and 
transformed into either competent UMAA2616 or MEW123 GAS. codY-null GAS was 
cultured in THY supplemented with 100 µg/mL streptomycin and 100 µg/mL 
spectinomycin. All cultures were grown under anaerobic conditions. 
 
Streptokinase activity assay 
Cultures were grown in 2xYT (Novagen, Darmstadt, Germany) as described above in the 
presence of either 50 µM CCG-2979132 (treated) or 1% DMSO (untreated) for 16 hours at 
37°C. Cells were separated from supernatant by centrifugation at 6800g for 10 minutes at 
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4°C. The supernatant was then concentrated 10-fold using size exclusion concentrator 
columns (10 kDa cutoff, Merck Millipore Ltd, Cork, Ireland). SK activity in the 
supernatant was assayed as previously described.132, 144 Briefly, 20 µL of supernatant was 
added to 100 uL Tris-buffered saline (50 mM Tris, 150 mM NaCl, pH 7.4; TBS), 10 µL 
citrated human plasma, and 10 µL S-2403 (1 mg/mL; Chromogenix, Bedford, MA) in a 
96-well plate. Absorbance at 405 nm was measured following 2 h incubation at 37°C, 
and SK activity was calculated relative to SK activity in wildtype (CodY+ ; WT ), 
untreated GAS. 
 
Phage display library construction 
UMAA2616 GAS (100 mL) was grown for 16 hours at 37°C in THY-streptomycin 
supplemented with 20 mM glycine. Cells were pelleted by centrifugation, washed with 
TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and lysed for 1 hour at 37°C with lysozyme 
and mutanolysin (Sigma-Aldrich, St. Louis, MO). Lysed pellets were further disrupted by 
three freeze-thaw cycles before phenol/chloroform extraction of nucleic acids, which 
were treated with RNase and purified by phenol/chloroform extraction. The resulting 
genomic DNA was sheared using sonication (5 min cycles of 30 s of sonication, 30 s of 
rest) yielding DNA fragments between 100-1200 bp which was verified on a 1% agarose 
gel. Adapters pre-cut for annealing into pAYE phagemid44 digested with NotI and AscI 
were ligated to sheared and end-repaired DNA, and subsequently purified by gel 
extraction (300-1200 bp) (Table 2-2). Adapted GAS genomic DNA fragments were 
cloned into the AscI and NotI digested-pAYE (pAYE-GAS) vector and electroporated 
into XL-1 Blue MRF’ E. coli (Agilent Technologies, Santa Clara, CA). The depth and 
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insert efficiency was determined by titering transformed cells and performing PCR on 
single colonies using primers annealing outside the insertion site (5’- 
TTCATGCTGCCGGCTTTCTCGG -3’ and 5’-
TCGTCATCGTCCTTGTAGTCACCACCA-3’; Table 2-1). GAS DNA fragments in 
frame with the N-terminal signal peptide and C-terminal FLAG tag should be translated 
and displayed on the phage surface as a C-terminal FLAG-tag, E-tag, pIII phage coat 
protein fusion. 44 
 
Phage production and purification 
Phage were prepared as previously reported.44 Briefly, E. coli harboring pAYE-GAS 
were grown in LB Broth (Invitrogen, Carlsbad, CA) supplemented with 100 µg/mL 
ampicillin and 2% glucose at 37°C to log phage (OD600 0.3-0.4) before transfection with 
M13KO7 helper phage (GE Healthcare, Chicago, IL) at a multiplicity of infection of 
approximately 100 for 1 hour at 37°C. Infected cells were pelleted by centrifugation at 
4250g for 10 minutes at 4°C and then resuspended in 2xYT supplemented with 100 
µg/mL ampicillin and 30 µg/mL kanamycin and cultured at 30°C for 16 hours. Cells were 
pelleted (4250g, 10 min, 4°C) and the phage-containing supernatant was cleared of 
remaining insoluble material by centrifugation (4750g, 10 min, 4°C). Supernatant was 
decanted and phage were precipitated by addition of 0.16 volume of 20% polyethylene 
glycol-8000/2.5 M NaCl and incubation on ice overnight before centrifugation at 20,000g 
for 20 min at 4°C. The phage pellet was resuspended in sterile TBS containing 0.005% 
Tween-20 (TBS-T). Phage titer was determined by transducing naïve XL-1 Blue MRF’ 
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E. coli grown to log phase for 1 hour at 37°C and plating on LB-agar supplemented with 
100 µg/mL ampicillin and 2% glucose. 
 
Phage screen 
Magnetic protein G beads (New England BioLabs) were washed twice with TBS before 
incubation with 5 µg of either a polyclonal anti-SK (PA1-85891, Pierce, Rockport, IL) or 
anti-streptococal pyogenic exotoxin C (speC) (ab53404, Abcam, Cambridge, UK) 
antibody for 1 hour at room temperature. Beads were then blocked with TBS containing 
5% bovine serum albumin (TBS-BSA). pAYE-GAS phage were incubated with antibody 
conjugated beads for 2 to 4 hours at 4°C before being washed with TBS-BSA five times. 
Specifically bound phage were eluted by enterokinase (EK) cleavage (New England 
BioLabs) in EK Elution Buffer (20 mM Tris-HCl, 50 mM NaCl, 2 nM CaCl2, 5% bovine 
serum albumin, pH 8.0). EK cleavage occurs at peptide sequence DDDDK, in the FLAG 
tag, which is cloned between the pIII coat protein and displayed GAS peptide. Cleavage 
reactions were performed for 16 hours at 4°C. Eluted phage were subjected to sequencing 
as described below. 
 
Phage sequencing 
The GAS insert of eluted pAYE-GAS phage was amplified using primers external to the 
insertion site (5’-TTCATGCTGCCGGCTTTCTCGG-3’ and 5’-
TCGTCATCGTCCTTGTAGTCACCACCA-3’; Table 2-1). PCR products were 
amplified and gel purified before being sheared by sonication to an average size of 300 
bp. Illumina adapters containing barcodes to allow for multiplexing were ligated, 
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followed by High-Throughput Sequencing (HTS) on an Illumina MiSeq Platform using 
paired end, 150 cycle reads (v3, Illumina, San Diego, CA). DNA sequences that 
contained a junction between the insert and pAYE backbone aligned as peptides to the 
GAS genome to determine the gene encoding for the displayed peptide product. 
Sequences that did not contain a vector between the insert and phagemid backbone were 
discarded because reading frame and orientation of insert could not be determined. 
 
Statistics 
Statistics for activity assays were done using GraphPad Prism 7 (GraphPad Software, La 
Jolla, CA). All groups were compared using 1-way analysis of variance (ANOVA) 





ska promoter contains potential CodY binding sites 
Although the CodY-DNA binding motif in GAS has not been established, motifs in B. 
anthracis and L. lactis have been identified.145, 146 Using these sequence motifs as a 
guide, analysis of the 200-base pair promoter sequence directly upstream of ska resulted 
in identification of two potential binding sites for CodY, located at 194 to 184 (5’-
TCGGAAgATT-3’) and 173 to 163 (5’-TTGGAAgATT-3’) bp upstream of the ATG 
start codon of ska (Figure 2-2). Additionally, electrophoretic mobility shift assays suggest 
that GAS CodY binds to the ska promoter sequence in a dose-dependent manner in the 
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presence of branched chain amino acids (valine) in vitro (Dr. Hongmin Sun, University 
of Missouri, personal communication). Taken together, these data support the hypothesis 
that CodY directly regulates SK expression via transcriptional control. 
 
Construction of codY-null GAS 
To test if CodY is required for CCG-2979-mediated inhibition of SK expression, a codY-
null strain of GAS was generated using homologous recombination as described in 
“Materials and Methods”. Although no colonies were obtained from the transformed 
UMAA2616 GAS, suggesting the spectinomycin resistance gene (aad9) was not 
successfully inserted into the bacterial chromosome, several colonies were obtained from 
the MEW123 GAS strain. Of the latter colonies, a single colony was selected, grown in 
the presence of spectinomycin, and disruption of codY confirmed by PCR analysis 
(Supplementary Figure 2-2). 
 
CodY is not required for CCG-2979-mediated inhibition of ska expression 
SK activity from both WT and codY-null strains of MEW123 GAS, was measured either 
in the presence or absence of CCG-2979. Treatment of codY-null GAS resulted in a 4-
fold decrease in SK activity, demonstrating that CodY is not the only target of CCG-2979 
(Figure 2-3). This was greater than the decrease seen in WT GAS when treated with 
compound (32.1% decrease in SK activity with treatment). There was a significant 
difference in SK activity of the codY-null GAS grown in the absence of compound 





GAS phage display library construction  
In an effort to identify the target GAS protein(s) interacting with CCG-2979, a phage 
display library expressing randomly sheared GAS DNA fragments covering the entire 
genome of UMAA2616 strain was constructed. The library contained 3.9×107 
independent clones, with 60.4% containing a GAS genomic DNA insert (2.34×107). After 
correcting for appropriate orientation of insert (50%), insert in frame at the 5’ (33.3%), 
and 3’ (33.3%) ends of the insert, the library was estimated to appropriately display a 
total of ~1.3×106 peptides encoded by independent GAS genomic fragments, with an 
average size of 525 bp, thus providing over 370-fold coverage of the GAS genome. 
 
To test the capacity of this library to display peptides encoded by the GAS genome, the 
library was panned against two commercial polyclonal antibodies (anti-SK and anti-
speC). Following selection, phage were sequenced and compared to the input (naïve) 
library in order to determine those clones that had been enriched during the screening 
process; however, peptides mapping to SK or speC were not the most highly enriched in 
either screen—suggesting that the pAYE-GAS phage display library screening approach 
was specific enough to detect the target peptide displayed on phage, but was not sensitive 
enough to detect those peptides above background within the library. (Supplementary 
Figure 2-3, Supplementary Tables 2-1 and 2-2). Because of the failure to enrich for 
specific interactions over background, the pAYE-GAS phage display library was not 
screened against CCG-2979 in order to identify GAS peptides that specifically interact 







Our data agrees with previous reports suggesting that the transcription regulator CodY 
positively regulates SK expression in GAS.135, 139 Compared to an untreated control strain 
of GAS, inactivation of CodY and treatment of WT GAS with CCG-2979 led to a 
significant reduction in SK activity. Treatment of CodY-null GAS with CCG-2979 led to 
a greater reduction of SK activity than either deletion of CodY or treatment with CCG-
2979 alone, suggesting that CodY is not directly required for CCG-2979-mediated 
inhibition of SK expression in GAS. Given the similar activity assays for codY-null 
untreated and WT-treated GAS, it is possible that CodY is indirectly involved in the 
mechanism of action. CodY regulates a significant portion of the GAS genome, including 
additional transcriptional regulators.139, 147 Additionally, SK expression is regulated by 
several factors other than CodY, including the control of virulence two component 
regulator system (CovRS), and the FasX regulatory RNA.139, 148-150 It is possible CCG-
2979 targets a GAS protein downstream of CodY signaling, accounting for the similar 
expression profiles of GAS treated with the small molecule and codY-null GAS.  
 
Of note, UMAA2616, the original strain of GAS used in the high-throughput screen to 
identify CCG-2979 as a small molecule inhibitor of SK expression, harbors mutations in 
both components of the Cov system, covR and covS (also known as csrRS), resulting in 
higher basal expression of SK. CodY and the CovRS system overlap significantly in 
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regulatory targets but are thought to mainly act antagonistically135, 139 To date, only one 
study has examined the effect of covRS and codY double mutants, constructed in serotype 
M49 GAS strain NZ131, and found that knockout of both regulators resulted in 
significantly increased levels of ska expression, above the increase seen in a covRS 
mutant alone.135 We were unable to generate a codY mutant in strain UMAA2616, 
possibly due to the existing covRS deletion in the M1 GAS strain. As a result, codY 
deletion and all SK activity assays were performed in the M28 MEW123 stain, which has 
an intact CovRS. It is possible that CCG-2979 behaves differently in strains lacking 
CovRS and further work could be undertaken with the existing double knockout strain to 
examine the effect of the compound in covRS and codY single and double knockout 
strains. Additionally, covRS could be deleted in our existing codY- MEW123 strain to 
determine if the compound behaves differently in different serotypes of GAS as serotypes 
M1 (UMAA2616) and M28 (MEW123) have been show to cause more invasive disease 
than M49 (NZ131).151 
 
Given the over 1800 genes in the GAS genome, construction of single mutant strains and 
individual testing for SK activity in response to treatment with CCG-2979 is not a viable 
strategy to determine GAS proteins involved in the mechanism of action. A higher 
throughput screening method, either genetic or biochemical, is required to more rapidly 
identify peptides that interact with or mediate the activity of the bioactive small molecule. 
A GAS phage display library could provide such a high throughput biochemical 
approach; however we were unable to validate our library with antibody 
immunoprecipitations. Upon examination of the sequencing obtained of the unselected 
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library, it was noted that peptides mapping to the β-galactosidase gene were 
overrepresented, with almost 4% of all reads mapping to this gene (Figure 2-4). Further 
analysis of these peptides revealed over 99% consisted of the peptide sequence PSSRW. 
This peptide sequence was also found to be the protein product produced when the two 
adapters used to ligate the blunted GAS genomic DNA into the phagemid formed 
heterodimers (Figure 2-5). Given this contamination with heterodimers, the actual depth 
of the library was likely much lower than estimated. 
 
Phage display libraries have been successfully generated from the genetic material of 
Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus equi, 
Staphylococcus epidermidis, and Staphylococus aureus but to date a phage display library 
constructed from GAS genomic DNA has not been reported. 45, 152-156 Additionally, these 
previously reported bacterial DNA phage libraries were screened using the iterative 
panning technique where the whole library was screened, selected phage were eluted and 
amplified in order to create a new library. After several rounds of this screening, 
selection, and re-amplification, only a handful of clones were selected and analyzed using 
a limited Sanger sequencing approach. This method does not allow for analysis of the 
diversity present in the naïve, unselected library and thus makes it difficult to determine 
if selected clones are true positive binders or simply the product of over-representation in 
the starting library. “High throughput” phage display, by comparison, uses HTS to 
analyze the diversity of inserts in the selected and unselected libraries to measure 
enrichment and depletions of specific peptides after a single round of selection with no 
re-amplification required. This not only saves time, but more importantly avoids 
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introducing baises into the library that might result from repeated re-amplification within 
E. coli. Although next-generation phage display is gaining popularity, to date it has 
mostly been used to examine libraries of synthetic peptides or mutagenic libraries 
constructed from a single gene, rather than whole genome libraries.41, 48, 56, 61, 157Analysis 
of highly diverse phage libraries with different insert sizes and reading frames made from 
whole genomes may prove too complicated to interpret after a single round of selection, 
even with the increased power of HTS. Nevertheless, we hope continued advances in 
HTS and techniques related to phage library construction will allow us to construct 
improved GAS phage display libraries in the future with the ultimate goal of screening 




Table 2-1: Primer sequences 
Primer 5’ è 3’ Sequence 
pSPC18::codY Cloning 
CodY-pSPC18 For TAAAACGACGGCCAGTGCCAATAACACAATGGCATCTCG 
CodY-pSPC18 Rev ATTCGAGCTCGGTACCCGGGAATCCCTGCACTTTCTAG 
codY Genotyping 
codY For AAAAAATGCCTAACTTATTAGAAAAAACTCG 
codY Rev TTCTATTTAAAATTCTTTTAATTTAGCAAAAATACC 
aad9 For GAATGGACTAATGAAAATGTAAATTTA 
pAYE Phagemid Sequencing 
pAYE-Sequencing For TTCATGCTGCCGGCTTTCTCGG 





Table 2-2: pAYE adapter sequences 
Adapter 5’ è 3’ Sequence 
Individual Adapters 
pAYE-AscI For CGCGCCATCGGGAGGAGGG 
pAYE-AscI Rev CCCTCCTCCCGATGG 
pAYE-NotI For TGGAGGAGGTGC 





Supplementary Table 2-1: Most enriched proteins identified in anti-SK pAYE-
GAS screen 
Rank Enrichment over 
Unselected 
Protein 
1 16.59 AAK33437, SPy_0405, Conserved hypothetical protein 
2 13.37 AAK33705, SPy_0762, Hypothetical protein 
3 13.17 AAK34236, SPy_1425, Hypothetical protein 
4 13.04 AAK34665, SPy_1979, Streptokinase (SK) 







Supplementary Table 2-2: Most enriched proteins identified in anti-speC pAYE-
GAS screen 
Rank Enrichment over 
Unselected 
Protein  
1 8.15 AAK33826, SPy_0910, Putative DNA topoisomerase IV (subunit C) 
2 7.88 AAK34771, SPy_2128, Hypothetical protein- phage associated 
3 7.25 AAK33570, SPy_0589, Hypothetical protein 
4 6.92 AAK33960, SPy_1073, 50S Ribosomal protein L7/L12 
5 6.80 AAK33761, SPy_0830, Putative pyrimidine regulatory protein 







Figure 2-1: CodY insertion mutant construction using pSPC18::codY 
codY was knocked out in GAS via insertional mutagenesis using pSPC18::codY. A 617 bp region of codY 
(+83 +699) was cloned into pSPC18, propagated in E. coli, and transformed into competent GAS. pSCP18 
contains no origin of replication recognized by GAS. Thus resistance to spectinomycin via aad9 is only 











Figure 2-2: Potential CodY binding sites in ska promoter 
Using the published CodY binding motifs from B. anthracis (top)145 and L. lactis (middle)146 as a guide, 
two potential CodY binding sites (-194 to -185 and -173 to -164, relative to the ATG start codon) were 
identified in the ska promoter directly upstream of ska (bottom). 
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Figure 2-3: Relative SK activity in WT and codY-null GAS strains grown in the 
presence of CCG-2979 or DMSO  
Relative to WT untreated GAS (control), a significant decrease in SK activity was observed in both WT-
treated and codY-null untreated. A significant decrease in SK activity was observed when CodY-null GAS 
was treated with CCG-2979, suggesting CodY is not directly required for CCG-2979-mediated inhibition 
of SK activity. Activity is reported as the mean relative activity ± SD (n=9). Significance was determined 






















































Figure 2-4: pAYE-GAS inserts mapping to GAS genes within unselected (input) 
library 
Input GAS phage display library was subjected to HTS and inserts in pAYE-GAS phagemid were mapped 
against the GAS genome to identify the gene to which the displayed peptide belonged. Protein products of 
GAS genes are displayed on the x-axis, organized by protein reference number. Peak height reflects 
frequency of identification relative to the total number of mapped reads. Red arrow denotes β-galactosidase 






















































































































































































Figure 2-5: Adapter dimer mapping to β-galactosidase 
Translation of adapter heterodimer formed when adapters used to ligate blunted GAS genomic DNA 
fragments into pAYE form heterodimers. 99.5% of all reads (11801/11864) mapping to β-galactosidase 
consisted of peptide sequence PSSRW, which maps to P184-W188 of β-galactosidase, suggesting 








Supplementary Figure 2-1: Microarray data from CodY KO GAS and CCG-102487 
shows overlap 
Broad categories in which genes were found to be significantly (Log2Fold-Change >2) up or down 
regulated by microarray analysis in either GAS treated with CCG-102487 (commercially available analog 
to CCG-2979). Gene categories highlighted in red were common between GAS treated with CCG-102487 
and a codY-null strain of GAS (red categories only). Relatively high degree of overlap led to hypothesis 
Gene regulator(s) 
Virulence Factor Production 
Down: 
-  Adhesins 
-  Antiphagocytic factors 
-  Cytolytic toxins 
-  Invasive factor  
      (streptokinase) 
Up: 
-  Extracellular 
    protease 
Global Regulation 
Down: 
-  Regulatory RNA 
 
Up: 
-  Two component  
    regulatory systems 
Up: 
-  Nucleotide utilization 
-  Branched chain amino 
   acid transportation 
Metabolism 
Down: 
-  Di/oligo-peptide  
    transportation 
-  Carbohydrate utilization 
-  Lipid biosynthesis 
Down: 
-  ATP synthase 







that CCG-2979 inhibited SK expression via a CodY-dependent mechanism. Figure adapted from Xu et al. 
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Supplementary Figure 2-2: PCR confirmation of codY disruption 
Positive disruption of codY by aad9 was confirmed using PCR. (A) Cartoon depiction of codY knockout via 
insertional mutagenesis and location of codY genotyping primers. (B) Agarose gel demonstrating positive 
disruption of codY. Expected product sizes for WT GAS was 794 bp using codY For/CodY Rev primer 










Supplementary Figure 2-3: Enrichment in pAYE-GAS following selection by 
immunoprecipitation 
Sequencing of GAS phage display library following selection using polyclonal antibodies raised against SK 
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insert to GAS peptidome. (A) Enrichment of eluted phage following selection with anti-SK polyclonal 
antibody. SK, denoted by red arrow, was identified as the fourth most enriched peptide, suggesting 
selection was not specific. Higher specificity was expected following library screening against a specific 
antibody. Top 5 most enriched proteins are listed in Supplementary Table 2-1. (B) Enrichment of eluted 
phage following selection with anti-speC polyclonal antibody. Red arrow denotes speC, which was 
identified as the eighth most enriched GAS peptide, again suggesting the screening approached lacked the 
specificity to enrich for specific binding interactions. Top 5 most enriched peptides from anti-speC screen 
are listed in Supplementary Table 2-2.  
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CHAPTER 3:  
COMPREHENSIVE ANALYSIS OF SINGLE AMINO ACID SUBSTITUTIONS 





Plasminogen activator inhibitor-1 (PAI-1, SERPINE1) plays a critical role in the control 
of thrombosis and hemostasis as the principle inhibitor of tissue-type and urokinase-type 
plasminogen activators (tPA and uPA, respectively).84, 85 tPA and uPA are serine 
proteases that activate the zymogen plasminogen to plasmin.86 Activated plasmin 
dissolves blood clots by degrading fibrin, an insoluble protein-complex that forms the 
structural backbone of most blood clots.87 Plasma PAI-1 down regulates the fibrinolytic 
response by inhibiting plasminogen activation, with deficiency of PAI-1 resulting in 
accelerated degradation of fibrin clots and a bleeding diathesis.88-90 Individuals 
homozygous for a null mutation in SERPINE1 display bleeding phenotypes that can 
range from mild to life threatening while heterozygous individuals are asymptomatic.91, 92 
 
PAI-1 belongs to the serine protease inhibitor (serpin) class of proteins.159 Serpins are 
suicide inhibitors that covalently bind to their target proteases.75 All inhibitory serpins 
share a common mechanism of action wherein a flexible reactive center loop (RCL) 
extends above the central structure of the molecule and acts as “bait” for the target 
protease by mimicking the natural substrate.70.	During hydrolysis of the P1-P1’ bond 
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within the RCL by the protease, a stable acyl intermediate covalent bond is formed 
between the newly generated C-terminal residue for the RCL and the active site serine, 
tethering the protease to the serpin.71, 72 This is followed by the energetically favorable 
insertion of the N-terminal residues of the RCL into the central portion of the molecule as 
β-strand 4 in β-sheet A (s4A), carrying the tethered protease to the opposite side of the 
molecule in a pole-to-pole transition.73 This structural transformation renders both the 
serpin and the serine protease inactive.74-76 Serpins can also undergo cleavage of the P1-
P1’ carbonyl bond without subsequent inhibition of the protease, an event termed 
substrate behavior.77 
 
Among human serpins, PAI-1 exhibits two unique properties. First, the mature protein 
lacks any cysteine residues facilitating large scale recombinant production in bacterial 
expression systems.102, 103 Second, PAI-1 undergoes a spontaneous transition from an 
active conformation to a more thermodynamically stable, but inactive, latent 
conformation.104 At physiologic temperature and pH, this latency transition occurs 
rapidly, with a half-life of approximately two hours.105, 106 During the latency transition, 
the N-terminal portion of the RCL spontaneously inserts into the central β-sheet as s4A 
via a mechanism that mirrors that which occurs during serine protease inhibition but 
renders the P1-P1’ residues of the RCL inaccessible and the serpin incapable of inhibiting 
its target protease.107 
 
Multiple studies have used targeted mutagenesis to examine the role of individual PAI-1 
residues and secondary structures in the latency transition (Reviewed in 160). Attempts to 
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rationally design a more stable variant of PAI-1, however, have resulted in mixed 
success.160. Mutations introduced in order to slow the insertion of the RCL into β-sheet A 
mostly resulted in decreased inhibitory activity due to substrate behavior of the mutant 
PAI-1, as the resulting rate of insertion and protease inhibition was slower than 
deacylation of the serpin:protease intermediate.161 Some of these mutations, however, did 
result in slight prolongation of the latency transition half-life.162-164  
 
Two previous studies used randomly mutagenized PAI-1 to perform an unbiased screen 
aimed at characterizing mutations that stabilize the active conformation and prolong the 
half-life of latency conversion.112, 114. Berkenpas et al designed a relatively low mutation 
frequency library (~3 mutations per molecule) and expressed the library in λ phage.114 
Screening this library for mutants capable of binding to tPA after prolonged incubation at 
37°C resulted in identification of 14 unique clones, including PAI-1 14-1B, which 
harbors four amino acid substitutions, has a significantly prolonged half-life of 145 hours, 
and was sufficiently stable for crystallization of the active form.114, 165 Stroop et al 
constructed a library of PAI-1 mutants displayed on the surface of M13 filamentous 
phage and performed a similar screen to identify stabilizing mutations.112 This library had 
a much higher mutation frequency (~10 mutations per molecule) and a total of 6 clones 
were identified with increased stability.112 Together, these two studies analyzed a 
combined total of 1.3x107 mutant clones, providing more than enough depth to survey the 
7,580 possible single amino acid substitutions within PAI-1 (379 amino acids × 20 
possible substitutions). However, only a combined 20 clones were sequenced from the 
selected material, ultimately identifying 84 substitutions that stabilize the active 
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conformation of PAI-1. As this dataset represents approximately 1.1% of all possible 
substitutions, the majority of the PAI-1 mutational landscape remains uncharacterized. 
Here we report the application of high throughput DNA sequencing (HTS) to screen a 
phage display library of randomly mutagenized PAI-1 in order to characterize the 
majority of the remaining mutational landscape of PAI-1.  
	
	
MATERIALS AND METHODS 
 
PAI-1 cloning  
For display of PAI-1 on the M13 filamentous bacteriophage, human SERPINE1 cDNA 
was cloned into the pAYE phagemid using  AscI and NotI restriction enzyme sites (New 
England BioLabs, Ipswitch MA).44, 102 The mature PAI-1 protein is N-terminally fused to 
a myc tag and C-terminally fused with a FLAG tag, E, tag, and a truncated M13 pIII coat 
protein, in tandem.   
 
PAI-1 mutant phage display library construction 
Wildtype (WT) SERPINE1 in pAYE was randomly mutagenized using the GeneMorph II 
Random Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) following 
manufacturer’s instructions. Briefly, primers used for PCR mutagenesis (5’- 
TTCTCGGCCTAGCCGGCCGG -3’ and 5’- 
GTCCTTGTAGTCACCACCACCTGCGGCC -3’, Table 3-1) covered the AscI and NotI 
restriction sites so as to conserve these sites for ligation of the restriction digested 
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amplicons into pAYE. After PCR, products were seperated on a 1% agarose gel and the 
band at ~1200 bp was gel extracted, digested with AscI and NotI, ligated into pAYE, and 
transformed into XL-1 Blue MRF’ E. coli (Agilent Technologies)166. Library depth was 
determined by titering transformed cells on LB agar (Invitrogen, Carlsbad, CA) 
supplemented with 100 µg/mL ampicillin and 2% glucose. 
 
Phage production and purification 
Phage were prepared as previously reported with slight modification to minimize PAI-1 
conversion to the latent conformation.44 Briefly, E. coli harboring pAYE- mutant PAI-1 
were grown in LB Broth (Invitrogen) glucose at 37°C to log phase (OD600 0.3-0.4) and 
infected with M13KO7 helper phage (GE Healthcare, Chicago, IL) at a multiplicity of 
infectivity of approximately 100, with incubation for 1 hour at 37°C. Cells were pelleted 
by centrifugation and then resuspended in 2xYT with ampicillin (100 µg/mL) and 
kanamycin (30 µg/mL; Sigma-Aldrich, St. Louis, MO). To induce PAI-1 production from 
the phagemid, IPTG was added to 2xYT (0.6 mM). To minimize the time for PAI-1 
latency transition though maintaining sufficient phage production, growth time was 
shortened from 16 hours at 30°C to 2 hours at 37°C. All subsequent phage preparation 
steps were carried out on ice. The PEG/NaCl phage precipitation step was also shortened 
from overnight to 30 minutes. After precipitation, the phage pellet was resuspended in 
sterile TBS containing 0.005% Tween-20 (TBS-T). Phage titer was determined by 
transducing naïve XL-1 Blue MRF’ E. coli grown to log phase for 1 hour at 37°C and 




uPA:phage displayed PAI-1 capture assay 
Phage displaying the A3 domain of von Willebrand Factor (VWF-A3; cloned into 
pAYE)44 were used as a negative control for binding to uPA. Phage displaying PAI-1 
were diluted in phage displaying VWF-A3 and then incubated with high molecular 
weight urokinase (HMW-uPA, Molecular Innovations, Novi, MI; 1.5 nM) for 30 minutes 
at 37°C. EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland) was added 
and incubated for 10 min before immunoprecipitation. Phage:uPA complexes were 
immunoprecipitated using magnetic protein G beads (New England BioLabs, Ipswitch, 
MA) charged with polyclonal anti-uPA antibody (Abcam Inc, Cambridge, UK; ab2412). 
Beads were washed 5x with TBS-BSA and eluted by enterokinase (New England 
BioLabs; 16U) digestion for 16 hours at 4°C in enterokinase elution buffer (20 mM Tris-
HCl, 50 mM NaCl, 2 mM CaCl2, and 5% BSA, pH 8.0). The eluted phage pool was used 
to infect naïve XL-1 Blue MRF’ E. coli. Eluted phage were quantified by counting the 
number of transduced colonies that grew in the presence of ampicillin. 
 
Colony screening 
To determine the composition of the phage pools before and after selection, single 
colonies of resistant bacteria were selected and DNA amplified by PCR using primers 
annealing outside the insertion site, to a region common to both pAYE-PAI-1 and pAYE-
VWF-A3 (5’-TTCATGCTGCCGGCTTTCTCGG -3’ and 5’- 
TCGTCATCGTCCTTGTAGTCACCACCA -3’). Phagemid inserts were distinguished 
by PCR product size (1271 bp for PAI-1 and 677 for VWF-A3). Mutation frequency of 
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PAI-1 mutant libraries was calculated by Sanger sequencing of the SERPINE1 inserts 
from selected individual colonies. 
 
PAI-1 latency screen 
100 µL resuspended phage were added to 800 µL TBS-BSA (5%) and incubated at 37°C 
for the desired time before adding HMW-uPA (1.5 nM; Molecular Innovations) and 
incubating for an additional 30 minutes at 37°C. EDTA-free protease inhibitor cocktail 
(Roche, Basel, Switzerland) was added and incubated for 10 min before 
immunoprecipitation. PAI-1:uPA complexes were immunoprecipitated, washed, and 
eluted as described above.  
 
PAI-1 phage display sequencing 
For Illumina high throughput sequencing (HTS), 150 bp overlapping amplicons were 
PCR amplified from pAYE-mutant PAI-1(Supplementary Tables 3-1 and 3-2). All primer 
pairs used to generate amplicons included a 5’-6N wobble (where N is A, C, G, or T) to 
provide sequence diversity and aid in base calling on the Illumina platform, resulting in a 
final PCR product size for each amplicon of 162 bp. PCR amplicon products were gel 
purified and prepared using NEBNext DNA Library Prep Master Mix Kit, following 
manufacturer’s instructions (New England BioLabs). Illumina sequencing adapters 
containing barcodes were purchased from Bioo Scientific (Austin, TX). 2x150 bp paired 
end HTS was performed using the Illumina HiSeq2500 platform (Illumina, San Diego, 
CA) at the University of Michigan DNA Sequencing Core (Ann Arbor, MI) or 




The Illumina HiSeq Platform was chosen for its relatively high accuracy among HTS 
technologies.167 Specifically, paired end sequencing was utilized to minimize the 
possibility of falsely identifying a sequencing error as a mutation in a PAI-1 insert. The 
error rate of Illumina HTS has been reported at 0.0026 errors per base for read 1 (R1, 
“forward read”) and 0.0040 errors per base for read 2 (R2, “reverse read”).168 Given these 
data, the probability of a sequencing error occurring at the same position in the forward 
and reverse reads (and thus being incorrectly classified as a true mutation) are ~1 in 
100,000 (0.0026 × 0.0040 = 1.04×10-5). Given current limits for read lengths on this 
platform, the mutagenized PAI-1 cDNA insert of 1.2 kbp was sequenced in 12 unique 
amplicons (Supplementary Table 3-2). 
 
Recombinant PAI-1 expression and purification 
Human SERPINE1 cDNA was subcloned from pAYE-PAI-1 into the pET Flag TEV LIC 
cloning vector (2L-T) using primers pET PAI-1 LIC For and pET PAI-1 LIC Rev 
(Supplementary Table 3-1), transformed into BL21(DE3) chemically competent E. coli 
(Invitrogen) and grown on LB agar supplemented with 100 µg/mL ampicillin. Resistant 
colonies were scraped into LB media supplemented with 100 µg/mL ampicillin and 20% 
glycerol and stored as glycerol stocks at -80°C. Point mutations were introduced using 
the QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) following 
manufacturer’s instructions. The full length of WT and all mutant PAI-1 constructs was 
confirmed by Sanger sequencing. The pET Flag TEV LIC cloning vector (2L-T) was a 




For recombinant PAI-1 expression and purification, E. coli containing pET-PAI-1 
constructs were grown at 37°C in LB media (100 mL) supplemented with 100 µg/mL 
ampicillin to mid-log phase (OD600 ~0.40-0.45) at which point IPTG was added (1 mM) 
and cells were grown for an additional 2 hours at 37°C. Cells were pelleted by 
centrifugation (3500g, 20 min, 4°C) and washed twice with 0.85M sodium chloride. The 
pellet was resuspended in suspension buffer (0.05M sodium phosphate, pH 7.0, 0.1M 
sodium chloride, 4 mM EDTA), T4 lysozyme (1 mg/mL) was added and the reaction 
incubated at room temperature for 30 min. Cells were subjected to three freeze-thaw 
cycles (1 min in liquid nitrogen, 5 min in 37°C water bath) and DNA was sheared by 
passing the crude extract through a 25 gauge needle 5-6 times. Lysates were cleared by 
centrifugation at 16000g for 20 min at 4°C. PAI-1 was purified from crude cell extracts 
using anti-FLAG agarose beads (Sigma-Aldrich) and eluted with 3X FLAG peptide 
(Sigma-Aldrich) following manufacturer’s instructions. 
 
PAI-1 activity assay 
To determine half-life for the latency transition, recombinant PAI-1 was incubated for 
varying amounts of time at 37°C and then its residual inhibitory activity against HMW 
uPA was measured as follows. Purified PAI-1 (7.5 nM) was incubated with HMW uPA 
(2.5 nM) in PAI-1 activity assay buffer (40 mM Hepes, 100 mM NaCl, 0.005% Tween-
20, pH 7.4) at room temperature for 30 min. Chromogenic substrate (zGly-Gly-Arg-
AMC, 50µM; Bachem, Bubendorf, Switzerland) was then added and residual uPA 
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activity was determined by measuring substrate hydrolysis for 10 minutes (λex 370 nM, 
λem 440 nM). 
 
Half-life calculation 
In order to determine half-life for PAI-1 displayed on phage or recombinant PAI-1, the 
number of phage recovered or relative activity of recombinant protein at a given time 
were plotted using GraphPad Prism 7 (GraphPad Software, La Jolla, CA). Within the 
program, nonlinear regression analysis was used to fit a one-phase decay curve to data 
following the equation: 
 
Equation 1:  
 
Where yo is equal to the y value at time (t) zero. As all values are relative to this point, yo 
is set to 1. B is the plateau, or the value of y at infinite time. For all half-life calculations, 
B was set to 0, resulting in the equation: 
 
Equation 2:  
 
Where K is the rate constant expressed as 1/h. Half-life was determined using the 
equation: 
 
Equation 3:  
 
y = (yo −B)e
(−Kt ) +B




Massively parallel half-life calculation 
To calculate a half-life of a particular clone based on the sequencing data, the frequency 
of reads mapping to an individual clone relative to all reads at that time point were 
multiplied by the estimated number of phage selected at that time point to estimate the 
number of phage displaying a particular clone. This was repeated for all time points and 
the number of a particular clone relative to the quantity at time 0 was determined, plotted 
in GraphPad, and a half-life was estimated as described above. As mutations exist on 
different amplicons, the half-lives were compared to the estimated half-life for phage 
with a WT sequence in the same amplicon as the mutation. 
 
Statistics 
Statistics for HTS were performed using DeSeq2 with adjusted p-value (padj) of <0.01 
considered significant.169 Statistics for activity assays were calculated using GraphPad 
Prism 7 (GraphPad Software).  
	
	
RESULTS AND DISCUSSION 
	
PAI-1 displayed on phage maintains its inhibitory function 
To determine if PAI-1 displayed on phage maintained its ability to covalently bind to and 
inhibit uPA, phage displaying WT-PAI-1 were diluted into phage displaying VWF-A3. 
This pool was screened against uPA as described in “Materials and Methods.” The 
selected phage pool showed marked enrichment for PAI-1 phage over VWF, 
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demonstrating that phage displayed PAI-1 maintains its inhibitory function with respect 
to uPA (Figure 3-1).  
 
PAI-1 displayed on phage exhibits latency kinetics similar to native PAI-1. 
In order for a phage display library to accurately identify mutations that increase the 
functional stability of PAI-1, the phage-displayed PAI-1 must undergo a latency 
transition similar to native PAI-1. To confirm this, the half-life for the latency transition 
of WT PAI-1 displayed on phage was determined over the course of a 72 hour incubation 
at 37°C by quantifying the number of functional phage immunoprecipitated in complex 
with uPA at each time point, relative to time 0 (Figure 3-2). The half-life of phage 
displayed PAI-1 was calculated to be 2.2 h (95% CI: 1.7 – 2.9h), similar to that of native 
PAI-1 (t1/2 ~ 2 h).105, 106 Importantly, in the absence of strong detergents, the latency 
transition half-lives of glycosylated PAI-1 produced in human cell lines and non-
glycosylated PAI-1 produced in E. coli are equivalent.170   
 
To exclude the possibility that loss of PAI-1 function was due to non-specific degradation 
or proteolysis of PAI-1 phage rather than transition to latency, a myc 
immunoprecipitation with anti-myc was also performed after prolonged incubation. PAI-
1 displayed on phage is fused to an N-terminal myc-tag. As the display of the myc tag is 
not dependent on the conformation of PAI-1, anti-myc antibody should bind equally well 
to active and latent PAI-1. Proteolysis of PAI-1 on pIII, however, should result in loss of 
the myc tag. The number phage recovered by myc-immunoprecipitation remained 
unchanged over the 72 h time course, confirming that the decrease over time in phage 
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recovered by uPA capture was due to loss of PAI-1 function secondary to latency 
transition (Figure 3-2). 
 
PAI-1 mutant phage libraries encompass broad coverage of potential single amino 
acid substitutions 
Two independent libraries (Library A and Library B) were constructed for use as 
biological replicates in HTS screening experiments. The libraries were similar in terms of 
mutation frequency and depth (Table 3-1). Deep sequencing of the libraries revealed that 
all possible single nucleotide substitutions (3411/3411) were represented within the 
libraries and 74% (5613/7580) of all possible amino acid substitutions were represented 
(Supplementary Figure 3-1). In examining the nucleotide substitutions identified by HTS, 
there was a bias for transitions (purine (A and G) to purine or pyrimidine (C and T) to 
pyrimidine mutations) over transversions (purine to pyrimidine, or vice versa) (Table 3-2, 
Supplementary Table 3-3). Though 1/3 of all possible nucleotide substitutions are 
transitions, they constituted 65.2% of substitutions within the libraries, consistent with 
the known bias of the Mutazyme II error prone polymerase (Agilent Technologies, 
GeneMorph II Random Mutagenesis Kit, Catalog #200550, Instruction Manual). A slight 
preference of the polymerase to introduce mutations at A-T over G-C base pairs was also 
observed (Supplementary Table 3-3). A challenge in generating all possible amino acid 
substitutions using random mutagenesis is the degeneracy of the genetic code with 
respect to amino acids; two amino acids (methionine and tryptophan) are coded by a 
single codon, while the remaining eighteen amino acids can all be made using at least two 
degenerate codons, with stop codons being coded for by three codons. Given this, it was 
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not surprising the most common substitution not represented in the library were those to 
tryptophan (10.5% of all missing substitutions). Somewhat surprisingly, substitutions to 
cysteine (coded by two codons) were more commonly absent (8.3%) than methionine 
substitutions (8.0%). (Supplementary Table 3-4). A recent bioinformatics approach 
demonstrated that when using single nucleotide substitution, which is what we expect in 
our library given our low mutation frequency, only 43.8% of all amino acid substitution 
events are possible and those that do occur tend to favor substitutions of amino acid with 
similar properties (polar, non-polar, charged, etc).171 Given these data, our library depth 
covers more mutations than would be expected. 
 
HTS confirms previously identified stabilizing and destabilizing mutations in PAI-1 
Mutant libraries were incubated for 0, 24, 48, and 72 hours at 37°C and then screened to 
select for PAI-1 mutants that retained their functional ability to bind uPA. Mutant 
libraries A and B were kept separate throughout screening and treated as biological 
replicates for DeSeq analysis. DeSeq was used to detect mutations that were significantly 
depleted (padj<0.01, Log2-Fold Change <0) or enriched (padj<0.01, Log2-Fold Change 
>0) relative to the unselected library at all time points individually and to all incubation 
time points (24, 48, 72h) combined (Table 3-3).  
 
Mutations that were significantly depleted were predicted to cause a destabilization of the 
active conformation of PAI-1. As expected, within the depleted populations, mutations 
resulting in substitution of a proline or stop codon were most represented (9.4 and 8.0% 
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of all depleted mutations, respectively, expected proportion assuming equal distribution: 
5%) (Supplementary Figure 3-3). 
 
Two previous studies have used libraries of randomly mutagenized PAI-1 to identify 
mutations that stabilize the active conformation and increase the half-life for the latency 
transition; combined these data identified a total of 84 amino acid substitutions that 
enhance PAI-1 stability.112, 114 The substitutions classified as stabilizing in our analysis 
included a majority of the previously identified mutations (Table 3-3). When the samples 
incubated for 24, 48, and 72 hours were compared to the unselected pool independent of 
one another, the most significantly enriched mutation identified at each time point was 
I91L, which has been previously reported as the most stabilizing single amino acid 
substitution (Supplementary Tables 3-5 – 3-7).114  
 
A limitation of the present study is the restriction of maximum amplicon size imposed by 
sequencing read lengths available on the Illumina platform. As a result, the entire length 
of PAI-1 cDNA insert (1.2 kb) could not be covered in a single sequencing read, instead 
requiring analysis of 12 independent amplicons (Supplementary Table 3-2). As a 
consequence, we are unable to determine whether multiple mutations identified in 
different amplicons occur in cis (together in the same PAI-1 phage clone) or trans (in 
different PAI-1 phage). Thus, potential nonadditive interactions between substitutions at 
two different positions (epistasis) can only be determined when both amino acid 
substitutions are located in the same amplicon. The most stable PAI-1 variant described 
by Berkenpas et al, 14-1B, harbored 4 mutations: N150H, K154T, Q319L, and M354I.114 
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Using recombinant expression, it was demonstrated that N150H alone was destabilizing, 
causing a reduction in the functional half-life of PAI-1 (1.3 hours) but when expressed in 
cis with K154T, the double mutant showed a greater increase in functional stability (t1/2 = 
6.7 hours) than for K154T alone (3.4 hours). 114 The same epistatic interaction could be 
assessed from our data since positions 150 and 154 are covered by the same sequencing 
amplicon (Table 3-4). when comparing the sequencing data from the unselected library to 
the pooled sequencing data from the prolonged incubation samples, no enriched 
mutations were detected at position 150, but significantly depleted mutations were (Table 
3-4). Three double mutations, with one of the mutations occurring at position 150 and the 
other at position 154 were found to be significantly enriched after prolonged incubation, 
suggesting an epistatic interaction between the two residues. A lone 150/154 double 
mutation was found to be significantly depleted, but the mutation at position 154 was a 
nonsense mutation, introducing a stop codon (Table 3-4). 
 
Because of its role in inhibition of tPA and uPA as well as its involvement in the latency 
transition, we chose to examine more closely the mutational landscape of the RCL 
(Figure 3-3). It is worth noting that because PAI-1:uPA complexes are 
immunoprecipitated with an anti-uPA antibody in our screen, any mutation that prevents 
the formation of a covalent bond between the serpin and protease (a dead mutant or 
mutant that exhibits substrate behavior) would be depleted. The RCL residues are thought 
to drive the specificity of serpins, especially at P1.83, 172, 173 Consistent with this model, 
our data found no enrichment, but substantial depletion, for alternative amino acids at P1 
(Figure 3-3). These data agree with previous saturation mutagenesis of the P1-P1’ 
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residues, which demonstrated the requirement for an arginine or lysine at the P1 position 
with little preference at P1’ for uPA inhibitory activity.174 Consistent with Sherman et al, 
our data demonstrated the P1’ position to be highly tolerant for substitution mutations, as 
seen with the lack of either significantly enriched or depleted mutations at the P1’ (Figure 
3-3).174 In the latent conformation of PAI-1, residues P14-P4 of the RCL insert into β-
sheet A as strand 4 (s4A), and it was theorized that introducing large, inflexible, or 
charged residues in this region would inhibit the insertion and stabilize the active 
conformation.162, 164 As this insertion is critical for the inhibition of target proteases, 
however, this hypothesis was proven incorrect by several studies which demonstrated that 
mutation of these residues to charged or less flexible amino acids resulted in cleavage of 
the RCL without protease inhibition, termed substrate behavior.162, 163, 175 In 1994 
Audenaert et al performed a proline-scanning mutagenesis, introducing proline mutations 
at P12 (A335P), P10 (S337P), P8 (T339P), and P6 (V341P).162 In all positions except P6, 
the substitution of a proline converted PAI-1 into a substrate for tPA; proline substitution 
at P6 resulted in a mutant that behaved similar to WT PAI-1.162 This result is mirrored 
exactly in our data: prolines were observed to be depleted at P12, P10 and P8, but not at 
P6 (Figure 3-3). Shortly thereafter, Lawrence et al demonstrated that substitution of a 
charged arginine for threonine at position 333 (P14) destroyed all inhibitory activity 
against tPA and uPA by converting the mutant PAI-1 to a substrate for the proteases.163In 
our mutation catalog, arginine was observed to be the most significantly depleted 




Finally, residues C-terminal to the scissile bond (P2’-P4’, amino acid positions 348-350) 
are more tolerant of mutations than the N-terminal segment, consistent with the 
requirement for insertion of this segment into β-sheet A during the transition to latency 
(Figure 3-3).107 
 
Characterization of stabilizing mutations not previously identified 
Three mutations not previously identified as stabilizing, I91F, K176E, and Y221C, were 
found in our enriched data set and selected for further analysis. All three mutations were 
among the top 25 most significantly enriched mutations at each time point 
(Supplementary Tables 3-5 – 3-7). I91F is similar to the previously identified I91L. 
K176E substitutes a negatively charged glutamic acid for a positively charged lysine. 
Y221C was the most significantly enriched substitution involving a cysteine substitution. 
FLAG-labeled rPAI-1 mutants were expressed, purified, and their half-lives measured 
over a 24 h time course, as described in “Materials and Methods” (Figure 3-4). rPAI-1 
I91F and K176E had significantly prolonged half-lives (p<0.05) compared to WT rPAI-1 
at the 95% confidence interval. The half-life of Y221C rPAI-1 was also prolonged but the 
difference was not significant (Table 3-5, Figure 3-4). It is possible that PAI-1 Y221C did 
not show a significantly prolonged half-life for the latency conversion because it required 
epistatic interactions with a mutation present on another amplicon. As discussed above, 
we are unable to determine if multiple mutations occurring on different amplicons occur 
in cis or trans and it is possible that Y221C in conjunction with another, distant, 
substitution is required for significant increase in structural stability. In such an instance, 
Y221C would be enriched due to stabilization of a molecule harboring the mutation along 
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with others, but we would be unable to determine which mutations must occur together if 
they are found on a different amplicon. 
 
Catalog of mutations that significantly affect PAI-1 stability 
By comparing the pooled sequencing data from the prolonged incubation time points with 
the data from the unselected library, we were able to generate a catalog of all mutations 
predicted to significantly stabilize or destabilize the active conformation of PAI-1. 
(Figure 3-5). Two-thousand and one of the 7,580 possible single amino acid substitutions 
(379 residues × 20 possible substitutions, including stop codons) exhibited statistically 
significant changes in stability including 492 enriched and 1,509 depleted. A computer 
algorithm developed in 2012, Sorting Intolerant From Tolerant (SIFT), predicts whether 
an amino acid substitution will affect protein function.176 SIFT analysis of PAI-1 
predicted that 4,194 of 7,201 (premature stop codons are not included in SIFT analysis) 
single amino acids substitutions would be deleterious to PAI-1 protein function 
(Supplementary Figure 3-4). Given this, the relatively high number of depleted 
mutations, predicted to destabilize the active conformation of PAI-1, identified in the 
present screen is not unexpected. The large discrepancy in the number of predicted 
deleterious mutations between our data and SIFT suggest high-throughput functional 
protein screens are of higher value than computer algorithms with respect to determined 
the effect of single amino acid substitutions on protein function. 
 
Massively parallel half-life determination 
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Our screen identified over 400 novel mutations that we predict to stabilize the active 
conformation of PAI-1 and slow the transition to latency. To determine the half-life for 
the full set of substitutions, we wanted to develop a high-throughput approach using 
sequencing read numbers and phage quantification at different time points. To test this, 
we calculated a predicted functional half-life for the recombinantly generated clone that 
showed significant prolongation of half-life, I91F and K176E, and the previously 
described most stabile point mutant, I91L, using a massively parallel approach as proof 
of principle (Figure 3-6). Half-lives estimated using this approached trended as expected, 
with I91L showing the most prolonged half-life, followed by I91F, and K176E. The 
calculated half-lives did not, however, agree with half-lives determined for the mutants 
by recombinant protein expression and activity assay (Table 3-6). We believe earlier time 
points are required in order to more accurately estimate the half-life of an individual 
mutant using this high throughput approach. Another limitation to this approach is that 
massively parallel half-life determination is likely complicated by epistasis within the 
library, as discussed above. 
 
Conclusions 
Our data show a high degree of agreement with previously published studies using 
random library of PAI-1 mutants to identify mutations that increase the functional half-
life. We also arrived at the same conclusions of several studies using targeted 
mutagenesis of the RCL. Taken together, these data demonstrate the power and validity 
of our high throughput phage display approach, especially to perform comprehensive 
analysis on over 5,600 mutations and their effect on the functional stability of PAI-1. 
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Using phage display coupled to HTS, we were able to perform these analyses in a 
massively parallel fashion and ultimately characterized 2,001 mutations as significantly 
affecting the functional half-life of PAI-1. This was not possible in previous studies using 
phage display to examine random mutations of PAI-1 and their effect on functional 
stability.112  
 
Currently, our ability to fully characterize mutations that stabilize the active conformation 
of PAI-1 is limited by the available sequencing technology. Due to DNA read size 
restrictions, we are unable to examine the role of multiple mutations occurring in tandem, 
hindering our ability to characterize epistatic interactions between two or more mutations 
acting synergistically to increase the half-life of PAI-1. This limits our ability to harness 
the full potential of this high throughput phage display approach and perform massively 
parallel latency transition half-life estimations and other possible assays such as 
massively parallel kinetics of uPA inhibition by PAI-1 mutants within the library. Other 
HTS platforms, such as Pacific Biosciences Single Molecule Real Time (SMRT) 
sequencing (https://www.pacb.com/products-and-services/pacbio-systems/rsii/) offer 
sequencing reads of far greater length that would allow sequencing of the entirety of a 
PAI-1 insert in the phagemid, but the error rate of this technology is in excess of 10%.167 
Such a high error rate would prove a substantial hurdle in examining a mutant library as it 
would be difficult to differentiate between a true mutation and a sequencing error..  
 
Another limitation with our libraries described herein is the lack of complete coverage of 
all possible substitution mutations. Although all possible single nucleotide substitutions 
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were present within the library, 26% (2,167/7,580) of all possible amino acid mutations 
were not observed. Synthetically constructed DNA oligonucleotides have been described 
as a viable alterative approach to generating mutant libraries and removes the biases 
associated with error prone DNA-polymerases.177 This approach, however, has not been 
applied to large DNA fragments (such as PAI-1) and may prove too expensive to be seen 
as a viable approach for mutating whole genes. 
 
Finally, we believe our methodology and results presented here have potential 
translational applications. In 2010 a “very long half-life” PAI-1 variant was shown to 
reduce total blood loss and bleeding time in mouse tail clip assays.178 This particular PAI-
1 variant had a half-life approaching 30 days, but required to formation of a disulfide 
bond between two cysteine substitution mutations and could not be produced in 
bacteria.179 Identification of a highly stable PAI-1 variant from our library that does not 
require the formation of a disulfide bond and could be recombinantly produced in 
bacteria might hold similar therapeutic applications. Additionally, our comprehensive 
profiling of the role of single amino acids substitutions on PAI-1 stability could be 
applied to help better understand the clinical significance of so-called “variants of 
unknown significance” (VUS) that are routinely identified in patients after genetic 
testing. By applying our approach to other proteins, this comprehensive profiling 
approach could help better understand if VUSs are in fact significant, and what role they 
might play in protein function. Additionally, our mutant library can be screened against 
other serine proteases to identify potential novel inhibitors or serpins with altered 
specificity. An obvious target is neutrophil elastase, which is normally inhibited by the 
71 
	
serpin α1-antitrypsin (A1AT).63 Deficiency of A1AT results in early-onset emphysema 
due to unregulated elastin breakdown in pulmonary tissue.78 Currently, treatment for 
A1AT replacement therapy involves weekly infusions of purified protein from plasma 
(https://www.nhlbi.nih.gov/health-topics/alpha-1-antitrypsin-deficiency). As PAI-1 can 
be made in large quantities recombinantly in bacteria, a novel variant of PAI-1 with 
altered specificity to inhibit neutrophil elastase could prove a valuable therapeutic in 
treating A1AT-deficieny. This treatment could be hindered, however, by the latency 
conversion of PAI-1. Alternatively, our screen could be used to describe a “hyper-stable” 
backbone of PAI-1, which could then be further mutated and tested for altered specificity. 
 
By developing a high throughput system with which to examine the role of individual 
amino acid substitutions on functional stability of PAI-1 we have been able to profile the 
largely-unknown mutational landscape. Additionally, we have laid the groundwork for 
future studies to perform massively parallel functional or enzyme kinetic assays on PAI-
1, as well as other studies which could have great therapeutic impact, such as rapid 




Table 3-1: PAI-1 phage display mutation library characteristics 
Library Mutation Frequency 
(mutations / molecule) 
Library Depth (clones) 
PAI-1 Random Mutation A 4.2 ± 1.8  8.04×106 





Table 3-2: Nucleotide mutation rates in mutant libraries 
Raw counts of mutations within pooled libraries 
 WT Nucleotide 




A 0 2121915 30542305 14167510 
C 6666641 0 1849651 18764140 
G 16202283 1564727 0 7517170 
T 10147583 19535798 1309239 0 
Frequency of mutations within pooled libraries 
 WT Nucleotide 




A  0.016 0.234 0.109 
C 0.051  0.014 0.144 
G 0.124 0.012  0.058 





Table 3-3: Number of significantly depleted and enriched mutations identified and 





Significantly enriched mutations 






Input vs 0 h 1103 429 57 69 
Input vs 24 h 1351 394 54 66 
Input vs 48 h 1556 517 57 69 
Input vs 72 h 1421 388 53 65 
Input vs Prolonged 
Incubation 






Table 3-4: Epistatic interactions between N150 and K154 













N150D / K154I 2.77 
N150S / K154I 2.74 
N150D / K154E 1.27 





Table 3-5: Half-lives of rPAI-1 mutants 
rPAI-1 Mutant Mean t1/2 (h) 95% CI t1/2 (h) Significant to  
p < 0.05 
WT 2.2 1.9 – 2.5  -  
I91F 5.4 4.4 – 6.7 Yes 
K176E 4.8 2.9 – 7.9 Yes 





Table 3-6: Latency transition half-lives estimated by a massively parallel approach 
Mutant Half-life estimated using 
massively parallel 
approach 
Mean (95% CI) 
Reported half-life 
Mean (95% CI) 
Ref. 
WT PAI-1 (phage 
displayed) (0, 2, 4, 8, 
12, 24, 48, 72 h time 
points) 
N/A 2.2 h (1.9 – 2.5 h) This Report (Figure 3-2) 
WT PAI-1 (phage 
displayed) (0, 24, 48, 72 
h time points) 
N/A 5.7 h (3.8 – 7.2 h) This Report (Figure 3-3) 
Amplicon 4 
WT 5.7 h (5.5 – 6.0 h) N/A N/A 
I91L 11.8 h (10.1 – 13.6 h) 18.4 ± 1.07 h Berkenpas et al114 
I91F 10.1 h (9.0 – 11.3 h) 5.4 h (4.4 – 6.7 h) This Report 
Amplicon 6 
WT 5.7 h (5.5 – 6.0 h) N/A N/A 
K176E 9.2 (8.3 – 10.1 h) 4.8 h (2.9 – 6.7 h) This Report 
Amplicon 7 
WT 5.8 h (5.5 – 6.0 h) N/A N/A 
K176E 9.4 h (8.5 – 10.3 h) 4.8 h (2.9 – 6.7 h) This Report 
Amplicon 8 
WT 5.7 h (5.5 – 5.9 h) N/A N/A 
Y210X 6.9 h (6.3 – 7.5 h) N/A N/A 





Supplementary Table 3-1: Primer sequences 
Primer 5’ è 3’ Sequence 



























































































































































Supplementary Table 3-2: PAI-1 residues 
covered by amplicons 
PAI-1 Amplicon Residues Covered 
1 V1 – D29 
2 A26 – A60 
3 G52 – W86 
4 E81 – L116 
5 P111 – K145 
6 H143 – K176 
7 Q174 – F208 
8 K207 – E242 
9 Y241 – L275 
10 L273 – S310  
11 S308 – S344 






Supplementary Table 3-3: Mutational bias of error 
prone polymerase 
 Number Proportion of Total 
Transitions 85044526 0.652 
Transversions 45344436 0.348 
AèN,	TèN	 73465327 0.563 






Supplementary Table 3-4: Substitutions absent from PAI-1 
mutant library 
Substitution Mutation Total Number Missing 
From Library 
Percentage of all 
missing substitutions 
D 115 5.8 
E 137 7.0 
K 118 6.0 
R 46 2.3 
H 134 6.8 
S 12 0.6 
T 23 1.2 
C 164 8.3 
Y 110 5.6 
N 83 4.2 
Q 149 7.6 
G 77 3.9 
A 46 2.3 
V 22 1.1 
L 24 1.2 
I 48 2.4 
M 158 8.0 
F 110 5.6 
W 207 10.5 
P 83 4.2 




Supplementary Table 3-5:  
Enrichment after 24 hour incubation 
Amplicon Mutation Log2 Fold 
Change 
4 I91L 2.96 
4 I91F 2.95 
12 F372V 2.84 
2 M45K 2.66 
4 I91M 2.46 
5 K145N 2.38 
7 K176E 2.35 
9 R271L 2.27 
8 D222Y 2.25 
6 K154I 2.20 
12 F372I 2.20 
9 L272R 2.18 
6 K145N 2.18 
12 E378D 2.15 
6 K176E 2.11 
10 D311V 2.08 
8 Y221C 2.07 
11 S331G 2.06 
3 W86L 2.06 
12 M354I 2.04 
6 L151M 2.03 
9 Y241H 2.01 
9 R271C 1.96 
6 M147K 1.91 
12 F372L 1.90 
	
25 most enriched mutations after 24 hour incubation at 37°C compared to unselected library. Previously 
identified mutations are in bold (exact) or italics (similar mutation at position). Novel mutations are listed 




Supplementary Table 3-6:       
Enrichment after 48 hour incubation 
Amplicon Mutation Log2 Fold 
Change 
4 I91L 3.86 
4 I91F 3.73 
12 F372V 3.64 
4 I91M 3.54 
2 M45K 3.46 
6 K154I 3.16 
5 K145N 3.15 
7 K176E 3.12 
9 R271L 2.97 
12 F372I 2.96 
12 F372C 2.90 
8 D222Y 2.88 
11 S331G 2.86 
6 K176E 2.84 
11 G332S 2.78 
12 E378D 2.75 
6 L169H 2.75 
11 G332D 2.69 
3 W86L 2.66 
6 K145N 2.65 
8 Y221C 2.63 
11 T333A 2.62 
9 Y241H 2.60 
9 R271C 2.57 
4 W86L 2.53 
 
25 most enriched mutations after 48 hour incubation at 37°C compared to unselected library. Previously 
identified mutations are in bold (exact) or italics (similar mutation at position). Novel mutations are listed 





Supplementary Table 3-7:  
Enrichment after 72 hour incubation 
Amplicon Mutation Log2 Fold 
Change 
4 I91L 4.19 
12 F372V 3.97 
4 I91M 3.87 
4 I91F 3.86 
2 M45K 3.78 
12 F372C 3.26 
12 F372I 3.19 
9 R271L 3.19 
6 K154I 3.07 
5 K145N 3.03 
8 D222H 2.97 
8 D222Y 2.93 
8 Y221C 2.93 
7 K176E 2.81 
2 S41W 2.80 
6 L169H 2.73 
9 R271C 2.73 
9 L272R 2.72 
12 F372L 2.72 
12 E378D 2.68 
11 G332D 2.65 
6 K176E 2.62 
11 G332S 2.59 
8 D222V 2.55 
9 Y241H 2.52 
 
25 most enriched mutations after 72 hour incubation at 37°C compared to unselected library. Previously 
identified mutations are in bold (exact) or italics (similar mutation at position). Novel mutations are listed 







Figure 3-1: Phage-displayed PAI-1 binds HMW-uPA 
Phage displaying WT PAI-1 were diluted into phage displaying the A3 domain of VWF at a ratio of 1:9. 
By analyzing single colonies with primers common to both the PAI-1 and VWF phagemid, the mean 
proportion of PAI-1 within the unselected (Input) library was 0.097. After selection, the mean proportion of 
PAI-1 was increased to 0.972. Mean proportion of phage ± SD is displayed, N=3, 96 colonies selected for 






























Figure 3-2: Latency transition of PAI-1 displayed on phage  
Relative quantity of phage recovered by either uPA complex formation and anti-uPA immunoprecipitation 
(red) or myc immunoprecipitation (blue) over 72 hours. PAI-1 displayed on phage experiences a latency 
transition with a half-life of 2.2 hours (95% CI: 1.7 – 2.9h), similar to that of native PAI-1 (t1/2 ~ 2h). Myc-
immunoprecipitation (blue) shows no significant decrease in number of phage recovered after 72 hour 
incubation. Mean phage ± SD relative to amount immunoprecipitated at time 0 is plotted. N=3 per group 
for all time points. 
	 	
























Figure 3-3: Mutational landscape of PAI-1 RCL 
Log2 fold change of mutations within the RCL of PAI-1 found to be significantly (padj<0.01) enriched or 
depleted in the prolonged incubation subset (24, 48, 72 hours) compared to unselected library. Amino acids 
above the x-axis are enriched (Log2 fold change >0) while amino acids below the x-axis are depleted (Log2 
fold change < 0). Height of letter corresponds to Log2 fold change. Residues are color coded by properties: 
acidic (negatively charged) residues in red, basic (positively charged) residues in blue, polar amino acids in 




















































































































































Figure 3-4: Half-life of recombinant PAI-1 mutants 
Recombinant PAI-1 mutants were expressed, purified and half-lives were determined as described in 
“Materials and Methods.” I91F and K176E demonstrated a significantly prolonged half-life compared to 
WT PAI-1. Y221C demonstrated a prolonged half-life but the difference was not significant (Table 3-5). 
Mean relative PAI-1 activity ± SD is plotted. Significance was determined using the 95% confidence 





















































































































Figure 3-5: Catalog of the effect of all single amino acid substitutions on the 
functional stability of PAI-1 
Log2 fold change of all mutations found to be either significantly depleted or enriched when comparing the 
prolonged incubation group to the unselected pool. Map in displays the level of enrichment (blue) or 
depletion (red) of the individual mutations that were altered significantly from the unselected library. Green 
represents the WT amino acid at each position. Mutations in light gray were either not present in the 
starting library or were not significantly enriched nor depleted after selection. 
	
	 	





































































Figure 3-6: Massively parallel latency transition half-life estimation 
Estimation of the latency transition half-life using a massively parallel approach for mutations occurring in 
amplicon 4 (A), amplicon 6 (B), amplicon 7 (C), and amplicon 8 (D). All mutations with the exception of 
Y210X were estimated to have a significantly prolonged half-life relative to the estimate of half-life for the 
corresponding WT amplicon (Table 3-6). Mean relative phage ± SD relative to amount at time 0 is plotted. 




























































































































































Supplementary Figure 3-1: Mutations present within randomly mutagenized 
libraries 
HTS of Libraries A and B was used to determine the coverage of all possible amino acid substitutions 
within the unselected library. Mutations observed after sequencing are shown in gray, the WT residue is 
shown in green, and mutations not found in either library are shown in white. 74% (5613/7530) of all 










































































Supplementary Figure 3-2: Significantly enriched and depleted mutations within 
PAI-1 after prolonged incubation 
 
































































































































(A) All significantly enriched mutations (padj<0.01, Log2 Fold Change > 0) found within the PAI-1 mutant 
library when comparing samples subjected to prolonged incubation with the unselected pool. White 
indicates lower average Log2 fold change, purple indicates higher average Log2 fold change, and gray 
indicates mutation was not significantly enriched. Mutations to stop codons were purposefully omitted 
from graph as no stop codons were found to be enriched, as was to be expected. (B) All significantly 
depleted mutations (padj<0.01, Log2 Fold Change < 0) found within the PAI-1 mutant library when 
comparing samples subjected to prolonged incubation with the unselected pool. White indicates higher 
(closer to 0, less negative) average Log2 fold change, red indicates lower average Log2 fold change, and 
gray indicates mutation was not significantly depleted. Data was combined at categorized broadly into 







Supplementary Figure 3-3: Frequencies of mutations found within enriched and 
depleted pools 
Frequencies of substitution for each amino acid and stop codon found within the significantly depleted (A) 
or enriched (B) pool of mutations relative to unselected material after incubation for 0, 24, 48, 72 hours or 
the pooled prolonged incubation pool (24, 48, 72 hours). Mutations to stop codons and prolines are the 
most frequent mutations found within the depleted populations. In contrast to the significantly depleted 

















































































Supplementary Figure 3-4: Mutations predicted to be deleterious by SIFT 
Sorting Intolerant From Tolerant (SIFT)176 analysis predicted 4,194 (not including stop codon substitutions) 
possible amino acid substitutions to be deleterious to PAI-1 function.	
































































CONCLUSIONS AND FUTURE DIRECTIONS 
	
CONCLUSIONS 
Chapter 2 describes hypothesis-driven experiments aimed at deciphering the mechanism 
of action by which CCG-2979, a small bioactive compound, inhibits the expression of 
streptokinase (SK) in Group A Streptococcus (GAS). Based on previously published 
microarray data and identification of two possible binding sites in the SK promoter, the 
transcriptional regulator CodY seemed like a potential target of the compound. When 
CodY was knocked out in GAS, however, treatment with CCG-2979 still resulted in 
decreased SK activity, suggesting that CodY was not directly involved in CCG-2979-
mediated inhibition of SK expression or that it was not the sole target. Given this result, 
an unbiased screen using a GAS phage display library was designed and undertaken in 
order to identify GAS proteins that interact with the compound, described in the second 
portion of Chapter 2. This phage display library was unable to be validated, suggesting it 
would not prove a useful tool in characterizing the GAS-interactome with CCG-2979. It 
was subsequently discovered that the GAS phage display library contained a high degree 
of contamination resulting from heterodimeric end adapters. The high frequency at which 
this specific insert was observed within the pool of phagemids from the GAS phage 
display library suggests the depth of our library was far lower than expected. Despite our 
failure to validate the GAS phage display library, we believe phage display, especially 
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when coupled with high throughput sequencing (HTS), is a powerful technique for 
studying protein structure-function, as shown by our results in Chapter 3. 
	
The experiments and data in Chapter 3 more accurately represent the power of high 
throughput phage display. By screening two randomly mutagenized PAI-1 phage display 
libraries, we were able to comprehensively profile the largely-unknown mutational 
landscape of PAI-1 with respect to the latency transition half-life in a massively parallel 
fashion. When selected against uPA after prolonged incubation to promote that latency 
transition, 2,001 single amino acid substitutions (26.4% of all possible substitutions) were 
found to be significantly altered relative to the unselected library. 1,509 of these 
mutations were significantly depleted, including stop codons, mutations within the RCL 
known to convert PAI-1 from an inhibitor to a substrate of uPA162, 163, 175, and mutations 
at the P1 site that would be predicted to diminish or destroy the ability of PAI-1 to inhibit 
uPA.174 Contained within the pool of 492 mutations that were significantly enriched, and 
predicted to stabilize the active conformation, were the majority of mutations previously 
identified by two research groups using randomly mutagenized libraries of PAI-1 to 
identify stable mutants.112, 114 Taken together, these data suggest our library and approach 
to characterizing single amino acid substitutions is valid. We believe this approach to 
massively parallel comprehensive analysis of the mutational landscape has potential to 
offer insight into the true significance of “variants of unknown significance.” 
 
Given that over 400 previously uncharacterized single amino acid substitutions were 
identified as enriched after prolonged incubation, we attempted to design a high 
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throughput method to estimate half-lives for all mutants. The results obtained from this 
method did not agree with previously published half-lives or with those we calculated for 
recombinant PAI-1 mutants, likely due to the lack of early time points included in our 
calculations, a limitation that can easily be addressed with additional experiments which 





Group A Streptococcus phage display 
As no phage display libraries from GAS have been reported, the construction and 
characterization of such a library could be a valuable resource in understanding how GAS 
interacts with the human host. Our laboratory has a special interest in the coagulation 
cascade and endothelial cell heterogeneity. A GAS phage display library would prove 
useful in further dissecting the differences between vascular beds by screening the library 
for GAS proteins that specifically localize to the vasculature of certain organs. 
 
A potential limitation in the construction of the GAS phage display library was the choice 
of a phagemid vector designed for use with a helper phage system. Although phagemids 
allow for display of larger proteins on the surface of phage, mutations that alter the 
reading frame of the phagemid encoded pIII are tolerated. A phagemid containing a DNA 
insert that is not in frame with pIII will not be displayed on the surface of the phage, but 
because of the packaging signal, will still be packaged into a phage particle displaying 
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five copies of WT pIII on the surface. Only 1 out of every 18 clones will have an insert 
that is in the correct reading frame at the 5’ and 3’ ends and be in the correct 
orientation.19 This estimate is likely too conservative because it does not take into 
account inserts that might contain non-coding DNA or stop codons.181 Given this, in our 
current phagemid approach, close to 95% of phage produced will not display a GAS 
peptide on their surface, but will still contain a GAS insert in the phagemid. An 
alternative phage vector such as the fUSE23 or the hyperphage182 system might prove 
more useful in constructing a library from randomly fragmented GAS genomic DNA. 
These vectors contain only a single copy of the pIII gene, so only inserts that are in-frame 
with pIII will lead to successful phage production. 
 
Applications of PAI-1 mutant libraries 
We are interested in expanding the scope of our experiments to screen our mutant 
libraries against other serine proteases with the goal of engineering new protease 
inhibitors with therapeutic potential. As discussed earlier, PAI-1 can be made 
recombinantly in bacteria in large quantities102, 103, does not require glycosylation, and 
does not have any native cysteines, making it a versatile backbone on which to develop 
novel therapeutics. There is evidence of a naturally occurring point mutation in a serpin 
resulting in altered specificities of inhibition, in A1AT Pittsburgh. In this specific mutant, 
a substitution of arginine for methionine at the P1 residue results in the mutant A1AT 
acting as an antithrombin and causing lethal bleeding.83 Mutations leading to altered 
specificity have also been engineered. In 2014, Scott and colleagues generated a phage 
display library of A1AT Pittsburgh randomly mutated at the P7-P3 sites within the 
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RCL.111 They screened this library against thrombin to select for mutants capable of 
inhibiting the protease and identified two novel mutants that had a increased rate of 
thrombin inhibition relative to A1AT Pittsburgh.111 In 2017, Polderdijk et al introduced 
targeted single or combinatorial mutations into P2-P1’ of the A1AT Pittsburgh RCL with 
the goal of switching the specificity of the serpin from inhibition of thrombin to 
inhibition of activated protein C (APC).183 Based on protein modeling, this group 
predicted that large, positively charged residues at P2 and P1’ could preferentially inhibit 
APC over thrombin and subsequently demonstrated that mutation of the WT sequence 
from PRS to KRK at P2-P1’ resulted in a mutant A1AT Pittsburgh with altered 
specificity for APC.183 These studies demonstrate the ability to construct serpins with 
altered specificity, either through screening random mutant libraries or rational design, 
but both examined a very limited portion of a single serpin. Interestingly, these studies 
focused on affects of mutations within the RCL on specificity, but in 1990 Lawrence et al 
cloned the RCL of PAI-2 into PAI-1, replacing the native PAI-1 RCL and demonstrated 
that regions outside the RCL of PAI-1 are important for specificity of inhibition.184 Given 
this, an unbiased, high-throughput screen examining mutations across the entire molecule 
of PAI-1, such as we have outlined here, may be needed in order to identify mutants with 
markedly altered specificity. 
 
Our mutant library can be screened against other serine proteases to 1) identify positions 
outside of the PAI-1 RCL that might be important for specificity and 2) engineer novel 
protease inhibitors with translational applications, such as a novel inhibitor of neutrophil 
elastase that could be produced recombinantly and used to treat A1AT deficiency. As 
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discussed in Chapter 1, A1AT deficiency results in uninhibited degradation of the 
pulmonary tissue by neutrophil elastase. Treatment involves weekly infusions with A1AT 
purified from human plasma. A stable PAI-1 variant that can be made recombinantly in 
bacteria and inhibits neutrophil elastase would have great therapeutic potential. Screening 
the library against neutrophil elastase is a logical starting point, as a PAI-1 variant that 
inhibits neutrophil elastase at rates comparable to its natural inhibitors has been 
previously described, providing a positive control we would expect to find in our selected 
population.185 Mutation of the P1 arginine in PAI-1 to alanine was shown to alter the 
specificity from tPA and uPA to neutrophil elastase. 185 Despite this, it was later shown 
that neutrophil elastase could cleave the mutant PAI-1 RCL at a different, non-inhibitory 
site within the RCL.185 This provides an argument for an unbiased screen using our 
randomly mutagenized library to identify novel inhibitor rather than targeted rational 
mutagenesis as other residues outside of the targeted region might affect the specificity or 
viability of a mutant PAI-1.  
 
The latency conversion of PAI-1 could complicate the ability to screen other proteases or 
develop stable therapeutics. To minimize this, a new randomly mutagenized library can 
be constructed from a stable PAI-1 variant. Options for such a backbone include, I91L, 
which has been described as the most stabilizing point mutation (t1/2: 18.4 hours), mutant 
14-1B, a mutant that harbors 4 different substitutions and has a half-life of over 140 





Finally, although there is ample knowledge that could be gained from screening our 
current PAI-1 mutant library, future directions should not be limited to just PAI-1. High 
throughput phage display is a powerful technique that can and hopefully will be applied 
to other proteins in order to characterize novel binding interactions, novel functions, or 
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